Compositions for targeted imaging and therapy

ABSTRACT

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application60/908,332, filed Mar. 27, 2007. The contents of U.S. provisional patentapplication 60/908,332 are incorporated by reference as though fullydisclosed herein.

TECHNICAL FIELD

The present invention relates to the field of radiochemistry, nuclearimaging, radionuclide therapy and chemical synthesis. More particularly,it concerns a strategy for radiolabeling target ligands. It furtherconcerns methods of using those radiolabeled ligands for imaging,radionuclide therapy and tissue-specific disease imaging.

BACKGROUND OF THE INVENTION

Diagnostic imaging techniques such as computed tomography (CT) andmagnetic resonance imaging (MRI) provide anatomical information aboutdisease sites. While these modalities are commonly-used for monitoringchanges in tumor size, they cannot assess functional changes occurringwithin cells or tumors. As a result, functional imaging techniques suchas Positron Emission Tomography (PET) and Single Photon EmissionComputed Tomography (SPECT) have been experiencing explosive growth dueto advances in molecular imaging technology. New molecular imagingtargets for diagnosis and therapy have been developed to visualizedisease states and pathological processes without surgical explorationof the body. In particular, targeted radiopharmaceuticals offerpromising capabilities for the non-invasive assessment of thepathophysiology of diseases. Schillaci, O. % Simonetti, G., CancerBioether. Radiopharm. 19: 1-10 (2004); Paulino, et al, Semin. Nucl. Med.33: 238-43 (2003). However, radiopharmaceuticals suitable for clinicaluse have been limited, which has led to the recent development of newradiopharmaceuticals with improved sensitivity, specificity,signal-to-background ratio and biodistribution. Srivastava, S. C.,Semin. Nucl. Med. 26: 119-31 (1996); Gatley, et al, Acta. Radiol. Suppl.374: 7-11 (1990); Mason, N. S. & Mathis, C. A., Neuroimaging Clin. N.Am. 13 ,671-87 (2003).

PET is a non-invasive medical imaging technology that can generatehigh-resolution images of human and animal physiologic functions. Itsclinical applications include oncology, cardiology and neurology. PETimaging can be very effective in the detection of disease as well as inthe treatment planning and treatment follow-up phases, respectively. Themedical importance of PET imaging is due to the availability of multipleradiotracers which are composed of the cyclotron-produced radioisotopes:¹¹C, ¹³N, ¹⁵O and ¹⁸F.

Radioisotopes are often created by a cyclotron or via a generator-basedsynthesis protocol. Cyclotrons are large and costly systems, and as aresult, many medical imaging facilities must obtain their radioisotopesfrom cyclotron facilities that are significant distances away. The timeit takes to synthesize a radiopharmaceutical, and then deliver it to amedical imaging facility necessitates that the radioisotopes used havesomewhat longer half-lives than might otherwise be ideal.

While FDG-PET is an effective marker for metabolic imaging, limitedaccessibility and high cost have encouraged imaging research to broadenthe diagnostic capabilities of PET. Currently, investigators can usegenerators based on a parent-daughter (P/D) nuclidic pairing, wherein arelatively long-lived parent isotope (obtained from a cyclotron) decaysto a short-lived daughter isotope better suited for imaging. The parentisotope can be shipped to a clinical site and act as the source fromwhich the daughter isotope can be readily eluted. Generators of thistype are generally smaller and relatively inexpensive and therefore, aremore readily affordable for use on-site at the medical imagingfacilities.

Commonly used cyclotron-produced radionuclides (i.e. ¹¹C, ¹³N, ¹⁵O and¹⁸F) are covalently linked to targeting molecules and do not require theuse of a chelating moiety. This is in contrast with generator-producedradionuclides, which are typically radiometals, and use coordinationchemistry through the presence of a chelator for radiolabeling.Chelators which bind radiometals and are conjugated to biomolecules arereferred to as bifunctional chelating agents (BFCAs). Electron-richatoms such as nitrogen, oxygen, sulfur and phosphorus comprise thecoordinating portion of most BFCAs. Common BFCAs for radio metallicchelation include DTPA, hydrazinonicotinamide (HYNIC),mercaptoacetyltriglycine (MAG3), tetraaza compounds (i.e.1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] andmacrocyclic derivatives) and ethylenedicysteine (EC). Each BFCApossesses various combinations of electron-donating atoms for metalchelation.

The selection and conjugation of BFCAS to biomolecules are carefullydesigned to produce minimal structural alterations to avoid disturbingthe targeting activity of the ligand. BFCAs serve two main purposes: 1)to coordinate the radiometal and 2) to provide a molecular backbone thatcan be modified with functional groups for attachment to the targetingbiomolecule. Conjugation of a BFCA to a biomolecule will alter thephysical and biological characteristics of the biomolecule. BFCAs suchas DTPA will dramatically increase the hydrophilic character of abiomolecule and lead to increased renal excretion. Macrocyclics (e.g.,tetraaza chelators), on the other hand, can be modified to obtainsuitable pharmacokinetics allowing for conjugation to both lipophilicand hydrophilic ligands, and are capable of chelating a variety ofradionuclides.

Improving of scintigraphic tumor diagnosis, prognosis, planning, andmonitoring of treatment of cancer is intimately linked with thedevelopment of more tumor-specific radiopharmaceuticals. The applicationof molecular targets for cancer imaging, therapy, and prevention is themajor focus of molecular imaging research. The use of PET and SPECT fortumor characterization is being enhanced through the development ofnovel radiolabeled ligands, antibodies, and therapeutic agents. As aresult, molecular nuclear medicine is improving methodologies for themonitoring of tumor response to treatment, differential diagnosis, andprediction of therapeutic response through the development andcharacterization of novel radiotracers.

Similarly, therapeutic nuclear medicine has benefited from the discoveryand validation of novel molecular targets. Identifying specificmolecules associated with certain diseases has lead to the developmentof targeted biomolecules which carry a therapeutic radionuclide as apayload. This results in specific delivery of radioactivity to thedesired site while sparing non-target organs from unnecessary radiationdose. ⁹⁰Y is a beta-emitting radioisotope which has been used clinicallyfor radionuclide therapy. A major concern with this approach is renaltoxicity associated with ⁹⁰Y and has lead to a shift in the fieldtowards using different therapeutic radionuclides. Also, althoughextensive clinical and preclinical studies have been undertaken withdifferent ⁹⁰Y-molecules, one major drawback exists: it is a pure betaemitter and must therefore use¹¹¹In as a “matching pair” surrogate forimaging, biodistribution and assessing dosimetry. Many assumptions aremade using this technique, therefore, much attention has been directedtowards practical application of therapeutic radionuclides that alsohave imaging capabilities for more accurate dosimetry calculations.Incorporating such radionuclides into targeted biomolecules capable ofradiometal chelation can provide the opportunity to selectively deliverradiation to a specific site for either diagnostic or therapeuticpurposes.

The present invention overcomes limitations in regards to theavailability of PET imaging in sites without a nearby cyclotron, thelack of targeted radionuclide therapy and other drawbacks of the priorart by providing a new radiolabeling strategy to target tissues forimaging. The invention provides versatile drug conjugates which can belabeled with various radioactive and non-radioactive metals and possesstissue-specific ligands, as well as methods for making the radiolabeledligands and for using them to image and treat tissue-specific diseases.

BRIEF SUMMARY OF THE INVENTION

The present invention is directed to the field of radiochemistry,nuclear imaging, radionuclide therapy, drug development and chemicalsynthesis. More particularly, it concerns a strategy for radiolabelingtarget ligands. It further concerns methods of using those radiolabeledligands for imaging, radionuclide therapy and tissue-specific diseaseimaging.

In one aspect of the present invention there is a composition comprisinga TA2S derivative conjugated to a therapeutic or diagnostic ligand andoptionally chelated to a metal, wherein said TA2S derivative has thegeneral formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and,

wherein one of (R₁ and R₃), or (R₂ and R₄) are —(CH₂)_(n)—(O)—R′,wherein each R′ group is the same or different from the other R′ groupand is either a hydroxyl group or a ligand; and wherein n=1-4.

In another embodiment of the composition, A₁, A₂, A₃, and A₄ are each—(CH₂—CH₂)— groups and having the following structure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TA2S derivative is a DO2Sderivative.

In another embodiment, the composition has the following structure:

(a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or,

(b) (R₁ and R₃) are ligands and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; and,

and said DO2S derivative is a DO2S derivative-1.

In one embodiment of the DO2S derivative composition, the ligand isselected from a group consisting of a proliferation targeting ligand, anangiogenesis targeting ligand, a tumor apoptosis targeting ligand, adisease receptor targeting ligand, a drug-based ligand, a microbialagent, a glucose-mimicking agent, a hypoxia targeting agent, anextracellular matrix targeting ligand, and any combination thereof. Inone embodiment of the DO2S derivative composition, the DO2S derivativefurther comprises at least one linker, wherein said at least one linkerforms a link to conjugate said DO2S derivative to said targeting ligand.In an embodiment comprising at least one linker, the at least one linkeris selected from the group consisting of ethylenediamine, aminopropanol, diethylenetriamine, aspartic acid, polyaspartic acid, glutamicacid, polyglutamic acid, lysine, polyethylene glycols, and anycombination thereof. In one embodiment of the DO2S derivativecomposition, the ligand is selected from the group consisting ofglucosamine, tetraacetate mannose, octreotide, Hedgehog ligands, EGFRtargeting molecules, nucleotides, nucleosides, cholesterol, estradiol,nanoparticles, carbon nanotubes, and any combination thereof. In oneembodiment of the DO2S derivative composition, the ligand is ananti-cancer compound. In one embodiment of the DO2S derivativecomposition, the ligand is a carbohydrate. In one embodiment of the DO2Sderivative composition, the DO2S derivative is chelated to a metalspecies. In one embodiment of the DO2S derivative composition chelatedto a metal species, the metal species is copper, cobalt, platinum, ironarsenic, rhenium, or germanium. In one embodiment of the DO2S derivativecomposition is chelated to a metal species, the metal species is aradionuclide. In one embodiment of the DO2S derivative composition ischelated to a radionuclide, the radionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu,⁶²Cu, ⁶⁴Cu, ⁶⁷ Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In,¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵Ac.In another embodiment, the radionuclide is ⁶⁸Ga or ¹⁷⁷Lu. In oneembodiment of the DO2S derivative composition, the ligand comprises adrug.

In another aspect of the present invention, there is a method for thetreatment or diagnosis of a medical condition in a subject comprising:

administering to a subject a composition comprising a TA2S derivativeconjugated to a therapeutic or diagnostic ligand and optionally chelatedto a metal,

wherein said TA2S derivative has the general formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and,

Wherein one of (R₁ and R₃), or (R₂ and R₄) are the same or different andare hydrogen or a ligand, and the other of (R₁ and R₃), or (R₂ and R₄)are —(CH₂)_(n)—C(O)—R′, wherein each R′ group is the same or differentfrom the other R′ group and is either a hydroxyl group or a ligand; andwherein n=1-4,

and,

optionally imaging said subject.

In another embodiment of the method for treatment or diagnosis, A₁, A₂,A₃, and A₄ are each —(CH₂—CH₂)— groups and having the followingstructure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TA2S derivative is a DO2Sderivative.

In another embodiment, the c method for the treatment or diagnosis hasthe following structure:

a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or,

(b) (R₁ and R₃) are ligands and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; and

and said DO2S derivative is a DO2S derivative-1.

In one embodiment of the method for treatment or diagnosis, the subjectis a mammal. In another embodiment, the subject is a human. In oneembodiment of the method for treatment or diagnosis using a DO2Sderivative, the DO2S derivative is chelated to a metal species. Inanother embodiment, the metal species is a radionuclide. In someembodiments, the radionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu,⁶⁷Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd,¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ²¹¹At, ²¹²Bi, or ²²⁵Ac. In otherembodiments, the radionuclide is ⁶⁸Ga or ¹⁷⁷Lu. In some embodiments ofthe method wherein the DO2S derivative is chelated to a metal species,the metal species is selected from the group consisting of divalent ionsof: an element of atomic number 21 to 29, 42, 44 and 57 to 83; and,trivalent ions of an element of atomic number 21 to 29, 42, 44, and 57to 83. In one embodiment of the method for treatment or diagnosis usinga DO2S derivative, the method further comprises administering radiationtherapy or surgery. In one embodiment of the method for treatment ordiagnosis using a DO2S derivative, the medical condition is cancer andsaid ligand is an anti-cancer compound. In some embodiments of themethod wherein the medical condition is cancer and said ligand is ananti-cancer compound, the method further comprises administration of asecond anti-cancer compound. In one embodiment of the method fortreatment or diagnosis using a DO2S derivative, the ligand is selectedfrom the group consisting of a proliferation targeting ligand, anangiogenesis targeting ligand, a tumor apoptosis targeting ligand, adisease receptor targeting ligand, a drug-based ligand, a microbialagent, a glucose-mimicking agent, a hypoxia targeting agent, anextracellular matrix targeting ligand, and any combination thereof. Inone embodiment of the method for treatment or diagnosis using a DO2Sderivative, the DO2S derivative further comprises at least one linker,wherein said at least one linker forms a link to conjugate said DO2Sderivative to said targeting ligand. In some embodiments of the methodsusing at least one linker, the at least one linker is selected from thegroup consisting of ethylenediamine, amino propanol, diethylenetriamine,aspartic acid, polyaspartic acid, glutamic acid, polyglutamic acid,lysine, polyethylene glycols, and any combination thereof. In oneembodiment of the method for treatment or diagnosis using a DO2Sderivative, the ligand is selected from the group consisting ofglucosamine, tetraacetate mannose, octreotide, hyaluronic acid, Hedgehogligands, EGFR targeting molecules, nucleotides, nucleosides,cholesterol, estradiol, nanoparticles, carbon nanotubes, and anycombination thereof. In one embodiment of the method for treatment ordiagnosis using a DO2S derivative, the ligand is an anti-cancercompound. In one embodiment of the method for treatment or diagnosisusing a DO2S derivative, the ligand is a carbohydrate.

In another aspect of the present invention, there is a kit for the thetreatment or diagnosis of a medical condition in a subject comprising,said kit comprising a composition comprising a TA2S derivativeconjugated to a therapeutic or diagnostic ligand and optionally chelatedto a metal, wherein said TA2S derivative comprises the general formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and,

wherein one of (R₁ and R₃), or (R₂ and R₄) are the same or different andare hydrogen or a ligand, and the other of (R₁ and R₃), or (R₂ and R₄)are —(CH₂)_(n)—C(O)—R′, wherein each R′ group is the same or differentfrom the other R′ group and is either a hydroxyl group or a ligand; andwherein n=1-4.

In another embodiment of the kit, A₁, A₂, A₃, and A₄ are each—(CH₂—CH₂)— groups and having the following structure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TA2S derivative is a DO2Sderivative.

In one embodiment of the kit wherein the composition comprises a DO2Sderivative, the DO2S derivative has the following structure:

a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or,

(b) (R₁ and R₃) are ligands and (R₁ ′ and R₂′) are the same or differentand are a ligand or hydroxyl group; and,

and said DO2S derivative is a DO2S derivative-1.

In one embodiment of the kit having a composition comprising a DO2Sderivative, the metal species is a radionuclide. In some embodiments,the radionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga,⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho,¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵ Ac. In some embodiments, theradionuclide is ⁶⁸Ga or ¹⁷⁷Lu. In some embodiments of of the kit havinga composition comprising a DO2S derivative, the kit further comprises anantioxidant. In some embodiments having an antioxidant, the antioxidantis vitamin C, gentisic acid tocopherol, phridoxine, thiamine, or rutin.In some embodiments, the kit further comprises a transchelator. In someembodiments having a transchelator, the transchelator is glucoheptonate,gluconate, glucarate, citrate, tartarate, DOTA,diethylenetriaminepentaacetic acid, or ethylenediaminetetraacetic acid.In some embodiments, the kit further comprises a reducing agent. In someembodiments having a reducing agent, the reducing agent is tin (II)chloride or triphenylphosphine. In some embodiments of the kit having acomposition comprising a DO2S derivative, the ligand is a tumortargeting ligand. In some embodiments of the kit having a compositioncomprising a DO2S derivative, the ligand is selected from the groupconsisting of a proliferation targeting ligand, an angiogenesistargeting ligand, a tumor apoptosis targeting ligand, a disease receptortargeting ligand, a drug-based ligand, a microbial agent, aglucose-mimicking agent, a hypoxia targeting agent, an extracellularmatrix targeting ligand, and any combination thereof. In someembodiments of the kit having a composition comprising a DO2Sderivative, the DO2S derivative further comprises at least one linker,wherein said at least one linker forms a link to conjugate said DO2Sderivative to said targeting ligand. In some embodiments having at leastone linker, the at least one linker is selected from the groupconsisting of ethylenediamine, amino propanol, diethylenetriamine,aspartic acid, polyaspartic acid, glutamic acid, polyglutamic acid,lysine, polyethylene glycols, and any combination thereof. In someembodiments of the kit having a composition comprising a DO2Sderivative, the ligand is selected from the group consisting ofglucosamine, tetraacetate mannose, octreotide, hyaluronic acid, Hedgehogligands, EGFR targeting molecules, nucleotides, nucleosides,cholesterol, estradiol, nanoparticles, carbon nanotubes, and anycombination thereof. In some embodiments of the kit having a compositioncomprising a DO2S derivative, the ligand is an anti-cancer compound. Insome embodiments of the kit having a composition comprises a DO2Sderivative, the ligand is a carbohydrate.

The foregoing has outlined rather broadly the features and technicaladvantages of the present invention in order that the detaileddescription of the invention that follows may be better understood.Additional features and advantages of the invention will be describedhereinafter which form the subject of the claims of the invention. Itshould be appreciated that the conception and specific embodimentdisclosed may be readily utilized as a basis for modifying or designingother structures for carrying out the same purposes of the presentinvention. It should also be realized that such equivalent constructionsdo not depart from the invention as set forth in the appended claims.The novel features which are believed to be characteristic of theinvention, both as to its organization and method of operation, togetherwith further objects and advantages will be better understood from thefollowing description when considered in connection with theaccompanying figures. It is to be expressly understood, however, thateach of the figures is provided for the purpose of illustration anddescription only and is not intended as a definition of the limits ofthe present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present invention, reference isnow made to the following descriptions taken in conjunction with theaccompanying drawing, in which: ZZZ

FIG. 1A-1C illustrates synthetic pathways for D02S derivative andschematic structures of D02S derivative 1; FIG. 1D provides a table ofvarious ligands and coupling agents.

FIG. 2 illustrates the preparation of the mono- anddi-aminosugar-containing DO2S derivative-1 labeled with radiometals.

FIG. 3A illustrates the preparation of D02S derivatives containingsomatostatin analogs labelled with radiometals. FIG. 3B illustrates thepreparation of the D02S derivative-1 containing somatostatin analogslabeled with radiometals.

FIG. 4 illustrates the preparation of D02S-EGF conjugates withradiometals.

FIGS. 5A and 5B illustrates the preparation of the dual isotope labeledof D02S derivative-I; D02S derivative-I conjugated to aliphatic andaromatic amines, amino acids, polyamines.

FIG. 6 illustrates the preparation of D02S-phosphate andphosphorothioate modified with lipophylic ligand.

FIG. 7 illustrates the preparation of D02S conjugates with goldnanoparticles and nanotubes.

FIG. 8 illustrates the modification of DO2S derivative-1 at the N-4and/or N-10 position.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, “a” and “an” include both the singular and the pluraland mean one or more than one. For example, “a ligand” means one ligandor more than one ligand.

In the field of nuclear medicine, certain pathological conditions arelocalized, or their extent is assessed, by detecting the distribution ofsmall quantities of internally-administered radioactively labeled tracercompounds (called radiotracers or radiopharmaceuticals). Methods fordetecting these radiopharmaceuticals are known generally as imaging orradioimaging methods.

An “alkyl” group refers to a saturated aliphatic hydrocarbon, includingstraight-chain, branched chain, and cyclic alkyl groups. Alkyl groupscan comprise any combination of acylic and cyclic subunits. Further, theterm “alkyl” as used herein expressly means an unbranched or branchedhydrocarbon chain having single bonds therein. The alkyl group may besubstituted or unsubstituted. When substituted, the substituted group(s)may be hydroxyl, cyano, alkoxy, ═O, ═S, —NO₂—N(CH₃)₂, amino, or —SH.Preferably, the alkyl group has 1 to 12 carbons. More preferably, it isa lower alkyl of from 1 to 7 carbons, more preferably 2 to 4 carbons,more preferably selected from the group consisting of —CH₂—CH₂—,—CH₂—CH₂—CH₂—, and —CH₂—CH₂—CH₂—CH₂—.

An “alkenyl” group means are unbranched or branched hydrocarbon chainhaving one or more double bonds therein. The “alkenyl” groups can beunsubstituted or substituted with one or more groups. When substituted,the substituted group(s) may be hydroxy, cyano, alkoxy, chloro, bromo,iodo, amino, thiolo. Preferably, the alkenyl group has 2 to 4 carbons,more preferably selected from the group consisting of —CH═CH—,—CH₂—CH═CH—, —CH═CH—CH₂—, —CH₂—CH═CH—CH₂, —CH═CH—CH═CH—. The term“alkenyl” groups include groups such as pentenyl, hexenyl, pentadienyl,hexadienyl.

An “alkynyl” group means an unbranched or branched hydrocarbon chainhaving one or more triple bonds therein. The “alkenyl” groups can beunsubstituted or substituted with one or more groups. When substituted,the substituted group(s) may be hydroxy, cyano, alkoxy, chloro, bromo,iodo, amino, thiolo. Preferably, the alkynyl group has 2 to 4 carbons,more preferably selected from the group consisting of —C≡C—, —CH₂—C≡C—,—C≡C—CH₂—, —CH₂—C≡C—CH₂, —C≡C—CH═CH₂—. The term “alkynyl” groups includegroups such as pentynyl, hexynyl, pentadiynyl, hexadiynyl.

As used herein, the word “compound” means a free chemical molecularentity or a chemical moiety that is pawrt of a larger molecular entity.Therefore, when reference is made, for example, to a targeting ligandbeing an anti-cancer compound, the language encompasses both ananti-cancer compound moiety incorporated with in a larger chemicalentity as well as the free anticancer compound.

The word “conjuugate” and “conjugated” is defined herein as chemicallyjoining within the same molecule. For example, two or more moleculesand/or atoms may be conjugated together via a covalent bond, forming asingle molecule. The two molecules may be conjugated to each other via adirect connection (e.g., where the compounds are directly attached via acovalent bond) or the compounds may be conjugated via an indirectconnection (e.g., where the two compounds are covalently bonded to oneor more linkers, forming a single molecule). In other instances, a metalatom may be conjugated to a molecule via a chelation interaction.

In one aspect of the present invention, there is a therapeutic and/ordiagnostic composition, the composition comprising a tetraaza compound(or any subgenus as defined below) conjugated to a ligand, the tetraazacompound optionally chelated to a metal species. The ligand may be adrug or targeting biomolecule or other therapeutic or diagnostic ligand.A tetraaza compound is defined herein as compound comprising thestructure:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and,

-   -   wherein (R₁-R₄) are the same or different and are hydrogen or        the following group: —(CH₂)_(n)—C(O)OR′, wherein n=1-4 wherein        the OR′ is a protecting group that is replaced by the ligand to        form the therapeutic and/or diagnostic composition. In the case        where any given R group of (R₁-R₄) is not hydrogen, and that R        group position is said to be substituted. Where three R groups        are hydrogen and one R group is non-hydrogen, the compound is        mono-substituted. Where two R groups are hydrogen and the other        two R groups are non-hydrogen, the compound is di-substituted,        etc. Preferably, the substitutions are the same and R′ is        selected from the group consisting of methyl, 2-chloroethyl,        2-bromoethyl 2-iodoethyl, ethyl, allyl, heptyl,        2-N-(morpholino)ethyl, 2,2,2-trifluoroethyl,        2,2,2-trichloroethyl, 2-cyanoethyl, ω-chloroalkyl, t-butyl,        benzyl, benzhydryl, phenacyl, p-bromophenacyl, α-methylphenacyl,        p-methoxyphenacyl, acetol, phenylacetoxymethyl, desyl,        diphenylmethyl, 1,3-dithianyl-2-methyl o-nitrobenzyl,        p-nitrobenzyl, carboxamidomethyl,        p-azobenzene-carboxamidomethyl, N-phthalimidomethyl,        trimethylsilyl, triethylsilyl, triisopropyl-silylmethyl,        triisopropylsilyl, t-butyldiphenylsilyl, t-butyldimethylsilyl,        isopropyl-dimethylsilyl, phenyldimethylsilyl,        di-t-butylmethylsilyl, cyanomethyl, methoxymethyl, methoxyethyl,        β-methoxyethoxymethyl, methylthiomethyl, methylthioethyl,        p-(methylthio)phenyl, benzyloxymethyl, tetrahydrofuranyl,        tetrahydropyranyl, pivaloyloxymethyl, phenyl,        2-(trimethyl-silyl)ethoxymethyl, trimethylsilyl,        2-(trimethylsilyl)ethyl, 2-(p-toluenesulfonyl)ethyl,        2-(p-nitrophenylsulfenyl)ethyl, 2-(2′-pyridyl)ethyl,        2-(p-methoxy-phenyl)ethyl, 1-methyl-1-phenylethyl,        2-(4-acetyl-2-nitrophenyl)ethyl, 3-methyl-3-pentyl,        dicyclopropylmethyl, 2,4-dimethyl-3-pentyl, cyclopentyl,        cyclohexyl, 2-methylbut-3-en-2-yl, 3-methylbut-2-prenyl,        3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl,        prop-2-ynyl, 2,6-dimethylphenyl, 2,6-diidopropylphenyl,        2,6-di-t-abutyl-methylphenyl, 2,6di-t-butyl-4-methoxyphenyl,        pentafluorophenyl, triphenylmethyl, bis-(o-nitrophenylmethyl),        9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-benzosuberyl,        1-pyrenylmethyl, 2-(trifluoro-methyl)-6-chromonylmethyl,        2,4,6-trimethylbenzyl, p-bromobenzyl, p-methoxybenzyl,        4-(methylsylfinyl)benzyl, 4-sulfobenzyl, 4-azido-methoxybenzyl,        4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino}benzyl,        piperonyl, 4-picolyl, p-benzyl 9-fluorenylmethyl, methallyl,        α-methylcinnamyl, and any combination thereof. Tetraaza        compounds are characterized, in part, by the presence of four        nitrogen atoms in a ring system and can also be referred as N4        compounds. In the chemical formula —(CH₂)_(n)—C(O)OR′, it should        be understood that the oxygen atom in the parentheses is a        carbonyl oxygen bonded by a double bond to the adjacent carbon,        while the other oxygen atom is bonded by a single bond to the        same carbon atom and to the R′ group forming an ester group.        Where there is more than one protecting group, the R′ groups can        be the same o r different. The OR′ is a protecting group that is        replaced by a ligand to form the therapeutic and/or diagnostic        composition. Thus, the term “tetraaza compound conjugated to a        ligand”, means either a tetraaza compound with one or more of        its OR′ groups replaced by a ligand, or if the tetraaza compound        has all R₁-R₄ as hydrogen, then one or more of said hydrogens is        replaced by a ligand.

The term “TA2S derivative” refers to a class of compounds which is asubgenus of tetraaza compounds. In another embodiment, there is acomposition comprising a TA2S derivative conjugated to a ligand andoptionally chelated to a metal, wherein said TA2S derivative has thegeneral formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and,

wherein one of (R₁ and R₃), or (R₂ and R₄) are hydrogen and the other of(R₁ and R₃), or (R₂ and R₄) are —(CH₂)_(n)—C(O)—OR′; wherein n=1-4. R′is as defined above for tetraaza compounds. The OR′ is a protectinggroup that is replaced by a ligand to form a therapeutic and/ordiagnostic composition. Thus, the term “TA2S derivative conjugated to aligand”, means either a TA2S derivative with one or more of its OR′groups or one or more of its hydrogens is replaced by a ligand.

In some embodiments of the composition, A₁, A₂, A₃, and A₄ are each—(CH₂—CH₂)— groups and said TA2S derivative is a DO2S derivative. DO2Sderivatives are a class of compounds and are a subgenus of TA2Sderivatives. The term “DO2S derivative conjugated to a ligand”, meanseither a DO2S derivative with one or more of its OR′₁ or OR′₂groups orone or more of its hydrogens is replaced by a ligand (with reference tothe structures below).

A general structure covering DO2S derivatives and DO2S derivativesconjugated to a ligand is as follows:

wherein n=1-4 and (a) (R₁ and R₃) are hydrogen and (R′₁ and R′₂) are thesame or different and are ligands or hydroxyl; or (b) (R₁ and R₃) arethe same or different and are ligands or hydrogen and (R′₁ and R′₂) arethe same or different and are ligands or hydroxyl groups.

In some embodiments of the DO2S derivative, R₁ and R₃ are hydrogen, n=1,and said DO2S derivative is a DO2S derivative-1. A DO2S derivative-1 isa class of compounds and is a subgenus of DO2S derivatives. A generalstructure covering DO2S derivative-1 and DO2S derivative-1 conjugated toa ligand is as follows (with R′₁ and R′₂ as defined above):

DO2S derivative-1 is a class of compounds and is a subgenus of DO2Sderivatives. The tetraaza compound may comprise a DO2S compound that isconjugated to a targeting ligand (via a covalent bond) and/or a linker(via a covalent bond) and/or a metal chelate (via a chelationinteraction). Both DO2S and DO2S derivative-1 are subgenera of tetraazacompounds; DO2S derivatives are a sub-genus of tetraaza compounds. Thetetraaza compounds, TA2S derivatives, and DO2S derivatives describedherein, when used in the compositions, methods, and kits of the presentinventions are the macrocycles (of macrocyclic compounds) of the presentinvention.

In other aspects of the invention, the above compositions are used inthe preparation of a diagnostic or therapeutic composition. Thediagnostic or therapeutic compositions include kits for use in treatmentor diagnosis of a medical condition. The following are non-limitingexamples of various embodiments of the kit. In preferred embodiments ofthe kit, the composition is a DO2S derivative chelated to a metal. Themetal is a radionuclide in some embodiments. Examples of radionuclide is⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu, ₆₇Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y,^(94m)Tc, ^(99m)Tc, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re,¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵Ac. The radionuclide is preferably ⁶⁸Ga or¹⁷⁷Lu. The kit may further comprise an antioxidant such as vitamin C,getistic acid, tocopherol, pyridoxine, thiamine, or rutin. The kit maycomprise a transchelator, such as glucoheptonate, gluconate, glucarate,citrate, tartarate, DOTA, diethylenetriaminepentaacetic acid, orethylenediaminetetraacetic acid. The kit may comprise a reducing agent,such as tin (II) chloride or triphenylphosphine. The ligand may be atumor targeting ligand. Other examples of the ligand include, but arenot limited to, a proliferation targeting ligand, an angiogenesistargeting ligand, a tumor apoptosis targeting ligand, a disease receptortargeting ligand, a drug-based ligand, a microbial agent, aglucose-mimicking agent, a hypoxia targeting agent, an extracellularmatrix targeting ligand, and any combination thereof. The kit mayfurther comprise at least one linker, wherein the at least one linkerforms a link to conjugate said DO2S derivative to the targeting ligand.Non-limiting examples of the at least one linker includeethylenediamine, amino propanol, diethylenetriamine, aspartic acid,polyaspartic acid, glutamic acid, polyglutamic acid, lysine,polyethylene glycols, and any combinations thereof. Other non-limitingexamples of the ligand include glucosamine, tetraacetate mannose,octreotide, hyaluronic acid, Hedgehog ligands, EGFR targeting molecules,nucleotides, nucleosides, cholesterol, estradiol, nanoparticles, carbonnanotubes, and any combination thereof. In some embodiments, the ligandis an anti-cancer compound. In some embodiments, the ligand is acarbohydrate.

As used herein the term “radionuclide” is defined as a radioactivenuclide (a species of atom able to exist for a measurable lifetime anddistinguished by its charge, mass, number, and quantum state of thenucleus) which, in specific embodiments, disintegrates with emission ofcorpuscular or electromagnetic radiation. The term may be usedinterchangeably with the term “radioisotope”.

The term “therapeutic agent” as used herein is defined as an agent whichprovides treatment for a disease or medical condition. The agent in aspecific embodiment improves at least one symptom or parameter of thedisease or medical condition. For instance, in tumor therapy, thetherapeutic agent reduces the size of the tumor, inhibits or preventsgrowth or metastases of the tumor, or eliminates the tumor. Examplesinclude a drug, such as an anticancer drug, a gene therapy composition,a radionuclide, a hormone, a nutriceutical, or a combination thereof.The therapeutic agent may be a ligand on a tetraaza compound, or on TA2Sor DO2S derivatives.

The term “tumor” as used herein is defined as an uncontrolled andprogressive growth of cells in a tissue. A skilled artisan is awareother synonymous terms exist, such as neoplasm or malignancy. In aspecific embodiment, the tumor is a solid tumor. In other specificembodiments, the tumor derives, either primarily or as a metastaticform, from cancers such as of the liver, prostate, pancreas, head andneck, breast, brain, colon, adenoid, oral, skin, lung, testes, ovaries,cervix, endometrium, bladder, stomach, and epithelium.

The term “drug” a used herein is defined as a compound which aids in thetreatment of disease or medical condition or which controls or improvesany physiological or pathological condition associated with the diseaseor medical condition.

the term “anticancer drug” as used herein is defined as a drug for thetreatment of cancer, such as for a solid tumor. The anticancer drugpreferably reduces the size of the tumor, inhibits or prevents growth ormetastases of the tumor, and/or eliminates the tumor. The terms“anticancer drug”, “anti-cancer drug”, and “anti-cancer compound” areused interchangeably herein.

As used herein the specification, “a”or “an” may mean one or more. Asused herein in the claim(s), when used in conjunction with the word“comprising”, the words “a” or “an” may mean one or more than one. Asused herein “another” may mean at least a second or more.

I. Tetraaza Compounds, TA2S Derivatives, and DO2S Derivatives

The present invention provides a method by which tetraaza compounds (orany subgenus as defined herein) which are chelators, may be conjugatedto drugs or biomolecules to produce novel compounds which may be usedfor purposes including imaging and radiotherapy. The tetraaza compoundis preferably a TA2S, more preferably a DO2S derivative, and mostpreferably DO2S derivative-1. Compounds and starting materials for theirsynthesis may be obtained from commercial source such as Macrocyclics(Dallas, Tex.) U.S. Pat. No. 5,880,281 describes a method for producingcertain tetraaza-macrocyclic compounds and is incorporated by referenceas though fully disclosed herein. In the remainder of the discussionherein, wherever reference is made to any one or more of 1) tetraazacompounds, 2) TA2derivatives, 3) DO2S derivatives, or 4) DO2Sderivative-1, the discussion is also applicable to and should beunderstood to be applicable to, any of the other aforementioned groupsof compounds. Tetraaza compounds, TA2S derivatives, and DO2S derivativesare all macrocycles.

Tetraaza compounds (as well as any subgenus or species thereof) can beused as chelators. For example, cyclam and other tetraaza compounds weretested for their ability to alleviate acute cadmium poisoning(Srivastava et al., 1996). U.S. Pat. No. 4,141,654 describes certaincompounds with structural similarity to tetraaza compounds that may beused to chelate actinide ions. U.S. Pat. No. 5,648,063 disclosescompounds with structural similarity to tetraaza compounds which canchelate metal ions and may also be used in certain NMR diagnosticprocedures. U.S. Pat. No. 6,071,490 utilizes a modified cyclen for PETimaging. U.S. Pat. No. 6,613,305 discloses Vitamin B₁₂ attached tovarious tetraaza compounds.

The present invention provides compositions for tissue specific diseaseimaging and treatment. The compositions of the invention generallyinclude a diagnostic radionuclide chelated by a tetraaza compound (thetetraaza compound preferably being a DO2S derivative and more preferablybeing DO2S derivative-1) and a tissue specific ligand conjugated to thetetraaza compound. In a preferred embodiment, the tetraaza compound isDO2S derivative-1, and the tissue specific ligand is conjugated to theDO2S derivative-1 through one or two of its acid arms and/or one or bothof the secondary amines. The tetreaaza compound forms coordinationbonds, with the radionuclide. As used herein, the term “conjugate”refers to a covalently bonded compound. When a a moiety is conjugated toanother moiety, there is a covalent bond linking the two moieties.

DO2S derivatives (the preferred compounds of the present invention) andDO2S derivative-1 (the most preferred compound of the present invention)are tetraaza ligands. Such compounds form very stable complexes withtransition metal ions and lanthamide series elements. Such chelatorshave been labeled with multiple radionuclides including ^(64/67)Cu,^(67/68)Ga, ^(86/90)Y, ¹¹¹In and ¹⁷⁷Lu. Macrocyclics have also beenshown to form very stable complexes with ^(99m)Tc on the basis ofefficient binding of the oxotechnetium group to three amine-nitrogenatoms.

Tetraaza compounds have been used for chelation of multipleradionuclides for diagnostic applications. Among these, ⁶⁸Ga-based PETagents (t_(1/2)=6 8 min, β“=89% and EC=11%) possess significant researchand clinical potential because the isotope can be produced from a⁶⁸Ge/⁶⁸Ga generator (t_(1/2)=271 days) on-site and provide a convenientalternative to cyclotron-based PET isotopes. The short half-life of ⁶⁸Gapermits applications with suitable radioactivity while maintainingpatient does to an acceptable level. Furthermore, the ⁶⁸Ga³⁺ cation canform stable complexes with many ligands containing oxygen, nitrogen andsulfur as donor atoms, making it suitable for complexation with a widerange of chelators and macromolecules.

A targeting ligand is a compound that, when introduced into the body ofa manual or patient, will specifically bind to a specific type oftissue. It is envisioned that the compositions of the invention mayinclude virtually any known tissue specific compound. Preferably, thetissue specific ligand used in conjunction with the present inventionwill be an anticancer agent, DNA topoisomerase inhibitor,antimetabolite, tumor marker, folate receptor targeting ligand, tumorapoptotic cell targeting ligand, tumor hypoxia targeting ligand, DNAintercalator, receptor marker, peptide, nucleotide, organ specificligand, antimicrobial agent, such as an antibiotic or an antifungal,glutamaate pentapeptide or an agent that mimics glucose. The agents thatmimic glucose may also be referred to as “sugars.”

Preferred anticancer agents include methotrexate, doxurubicin,tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide, tomudex,podophyllotoxin, mitoxantrone, camtothecin, colchicine, endostatin,fludarabin and gemcitabine. Preferred tumor markers include PSA, ER, PR,AFP, CA-125, CA-199, CEA, interferons, BRCA1, cytoxan p53, VEGF,integrins, endostatin, HER-2/neu, EGF, Hedgehog molecules, antisensemarkers or a monoclonal antibody. It is envisioned that any other knowntumor marker, therapeutic peptide, antibody fragment or any monoclonalantibody will be effective for use in conjunction with the invention.Preferred folate receptor targeting ligands include folate, methotrexateand tormudex. Preferred tumor apoptotic cell or tumor hypoxia targetingligands include annexin V, colchicine, nitroimidazole, mitomycin ormetronidazole. Preferred antimicrobials include ampicillin, amoxicillin,penicillin, cephalosporin, clidamycin, gentamycin, kanamycin, neomycin,natamycin, nafcillin, rifampin, tetracyclin, vancomycin, bleomycin, anddoxycyclin for gram positive and negative bacteria and amphotericin B,amantadine, nystatin, ketoconazole, polymycin, acyclovir, andganciclovir for fungi. Preferred agents that mimic glucose, or sugars,include neomycin, kanamycin, gentamycin, paromycin, amikacin,tobramycin, netilmicin, ribostamycin, sisomicin, micromicin,lividomycin, dibekacin, isepamicin, astromicin, aminoglycosides, glucoseor glucosamine.

In certain embodiments, it will be necessary to include a linker betweenthe 1) tetraaza compound, 2) TA2S derivative, or 3) DO2S derivative (inthe present invention any one or a combination of these three groups canserve as the macrocycle and may be referred to as the macrocycle), andthe tissue specific ligand. A linker is typically used to increase drugsolubility in aqueous solutions as well as to minimize alteration in theaffinity of drugs. While virtually any linker which will increase theaqueous solubility of the composition is envisioned for use inconjunction with the present invention, the linkers will generally be apoly-amino acid, a water soluble peptide, a single amino acid orpoly(ethylene) glycols. For example, when the functional group on thetissue specific ligand, or drug, is aliphatic or phenolic-OH, such asfor estradiol, topotecan, paclitaxel, raloxifene, or etoposide, thelinker may be poly-glutamic acid (MW about 750 to about 15,000),poly-aspartic acid (MW about 2,000 to about 15,000), bromo ethylacetate,glutamic acid or aspartic acid. When the drug functional group isaliphatic or aromatic-NH₂ or peptide, such as in doxorubicin, mitomycinC, endostatin, annexin V, LHRH, octreotide, and VIP, the linker may bepoly-glutamic acid (MW about 750 to about 15,000), poly-aspartic acid(MW about 2,000 to about 15,000), glutamic acid or aspartic acid. Whenthe drug functional group is carboxylic acid or peptide, such as inmethotrexate or folic acid, the linker may be ethylenediamine, orlysine.

The present inventors have also discovered that it is possible to bind asecond moiety to the polypeptide, such as a tissue targeting moiety, atherapeutic moiety, or an imaging moiety, such that the agent issuitable for multimodality imaging or radiochemotherapy. Suchconjugation reactions could be conducted, for example, in aqueous ororganic solvent conditions. The complexing of a metal ion to thepolypeptide improves water solubility of the agent, and allows for useof the agent in contrast enhancement targeted imaging.

While the preferred radionuclide for imaging is ⁶⁸Ga, it is envisionedthat other radionuclides may be chelated to the TA2S or DO2Sderivative-tissue specific ligand conjugates, or TA2S or DO2Sderivative-drug conjugates of the invention, especially for use astherapeutics. For example, useful therapeutic radionuclides are ⁵⁹Fe,⁶⁷Ga, ⁸⁹Sr, ⁹⁰Y, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re and¹⁸⁸Re, with ¹⁷⁷Lu being most preferable. Compositions containing suchtherapeutic radionuclides are useful for targeted delivery ofradionuclide therapy to a specific lesion in the body, such as breastcancer, ovarian cancer, prostate cancer (using for example, ¹⁷⁷Lu-DO2Sderivative-folate) and head and neck cancer (using for example,¹⁷⁷Lu-DO2S derivative-EGFR).

Specific embodiments of the present invention include ⁶⁸Ga/¹⁷⁷Lu-DO2Sderivative-glucose, ⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-glucosamine,⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-tetraacetate mannose, ⁶⁸Ga/¹⁷⁷Lu-DO2Sderivative-EGF, ⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-octreotide, ⁶⁸Ga/¹⁷⁷Lu-DO2Sderivative-hedgehog ligands, ⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-estradiol,⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-glutamate pentapeptide, ⁶⁸Ga/¹⁷⁷Lu-DO2Sderivative-oligonucleotides, ⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-aminoglycosides,⁶⁸Ga/¹⁷⁷Lu-DO2S derivative-nanoparticles, ⁶⁸Ga/¹⁷⁷Lu-DO2Sderivative-carbon nanotubes.

The present invention further provides a method of synthesizing aradiolabeled macrocycle-drug conjugate for diagnostic or therapeuticuse. For example, the method includes obtaining a tissue specificligand, admixing the ligand with DO2S derivative to obtain a DO2Sderivative-tissue specific ligand derivative, and admixing the DO2Sderivative-tissue specific ligand derivative with a radionuclide toobtain a radiolabeled DO2S derivative-tissue specific ligand derivative.The radionuclide is chelated to the TA2S or DO2S derivative via acoordination bond by the nitrogen and oxygen atoms. The tissue specificligand is conjugated, as described above, to one or both amino groupseither directly or through a linker. As required, such as in the case of^(99m)Tc and ¹⁸⁸Re, a reducing agent, preferably a dithionite ion, astannous ion or a ferrous ion, is used for radiolabeling.

The present invention further provides a method for labeling a tissuespecific ligand for diagnostic, therapeutic, or prognostic use. Thelabeling method includes the steps of obtaining a tissue specificligand, admixing the tissue specific ligand with a macrocycle to obtainan macrocycle-ligand drug conjugate, and reacting the drug conjugatewith ⁶⁸Ga or ¹⁷⁷Lu to form a coordination bond between the macrocycleand the ⁶⁸Ga or ¹⁷⁷Lu.

For purposes of this embodiment, the tissue specific ligand may be anyof the ligands described above or discussed herein. The reducing agent,which is required for ^(99m)Tc and ¹⁸⁸Re, may be any known reducingagent, but will preferably be a dithionite ion, a stannous ion or aferrous ion.

In another embodiment, the present invention provides a method ofimaging a site within a mammalian body. The imaging method includes thesteps of administering an effective diagnostic amount of a compositioncomprising a radiolabeled DO2S derivative-tissue specific ligandconjugate and detecting a radioactive signal from the radiotracerlocalized at the site. The detecting step will typically be performedfrom about 10 minutes to about 4 hours after introduction of thecomposition into the mammalian body. Most preferably, the detecting stepwill be performed about 1 hour after injection of the ⁶⁸Ga composition,or 24 after injection of the ¹⁷⁷Lu composition into the mammalian body.

In certain preferred embodiments, the site will be an infection, tumor,heart, lung, brain, liver, spleen, pancreas, intestine or any otherorgan. The tumor or infection may be located anywhere within themammalian body but will generally be in the breast, ovary, prostate,endometrium, lung, brain, colon or liver. The site may also be afolate-positive cancer or estrogen-positive cancer.

The invention also provides a kit for preparing a radiopharmaceuticalpreparation. The kit generally includes a sealed vial or bag, or anyother kind of appropriate container, containing a predetermined quantityof TA2S or DO2S derivative-tissue specific ligand conjugate compositionto label the conjugate with the desired radionuclide. In certain cases,the macrocycle-tissue specific ligand conjugate composition will alsoinclude a linker between the macrocycle and the tissue specific ligand.The tissue specific ligand may be any ligand that specifically binds toany specific tissue type, such as those discussed herein. When a linkeris included in the composition, it may be any linker as describedherein.

The components of the kit may be in any appropriate form, such as inliquid, frozen or dry form. In a preferred embodiment, the kitcomponents are provided in lyophilized form. The kit may also include anantioxidant and/or a transchelator. The antioxidant may be any knownantioxidant but is preferably vitamin C. Transchelators may also bepresent to bind unreacted radionuclide. Most commercially-available kitscontain glucoheptonate as the transchelator. However, glucoheptonatedoes not completely react with typical kit components, leavingapproximately 10-15% of unused material. This remaining glucoheptonatewill go to a tumor and skew imaging results. Therefore, the inventorsprefer to use DTPA, EDA or DOTA as the transchelator as they are cheaperand react more completely.

Another aspect of the invention is a prognostic method for determiningthe potential usefulness of a candidate compound for treatment ofspecific tumors. Currently, most tumors are treated with the “usual drugof choice” in chemotherapy without any indication whether the drug isactually effective against that particular tumor until months, and manythousands of dollars, later. The imaging compositions of the inventionare useful in delivering a particular drug to the site of the tumor inthe form of a labeled macrocycle-drug conjugate and then imaging thesite within hours to determine whether a particular drug is taken up andretained.

In that regard, the prognostic method of the invention includes thesteps of determining the site of a tumor with a macrocycle which isconjugated to a tumor specific cancer chemotherapy drug candidate,administering the composition to the mammalian body and imaging the siteto determine the effectiveness of the candidate drug against the tumor.Typically, the imaging step will be performed within about 10 minutes toabout 4 hours after injection of the composition into the mammalianbody. Preferably, the imaging step will be performed within about 1 hourafter injection of the composition into the mammalian body.

The cancer chemotherapy drug candidate to be conjugated to macrocyclesin the prognostic compositions may be chosen from known or yet to bedeveloped cancer chemotherapy drugs. Such drugs are known to those ofordinary skill in the art. There are many anticancer agents known to bespecific for certain types of cancers. However, not every anticanceragent for a specific type of cancer is effective in every patient.Therefore, the present invention provides a method of determiningpossible effectiveness of a candidate drug before expending a lot oftime and money on treatment.

Yet another embodiment of the present invention is a reagent forpreparing a scintigraphic imaging agent. The reagent of the inventionincludes a tissue specific ligand, having an affinity for targeted sitesin vivo sufficient to produce a scintigraphically-detectable image,covalently linked to a radionuclide binding moiety. The radionuclidebinding moiety is either directly attached to the tissue specific ligandor is attached to the ligand through a linker as described above. Theradionuclide binding moiety is preferably a tetraaza compound. Forexample, the tissue specific ligand may be covalently linked to one orboth acid arms of the TA2S derivative or DO2S derivative, eitherdirectly or through a linker and/or one or both of the secondary amines,either directly or through a linker as described above. The tissuespecific ligand may be any of the ligands as described above.

Suitable bifunctional chelators generally serve two main purposes: 1) tocoordinate the radiometal and 2) to provide a molecular backbone thatcan be modified with functional groups for attachment to the targetingmolecule. Conjugation of radiometal chelators can be applied to multipleclasses of compounds described below. In certain embodiments thesesubsequent bioconjugates could then be radiolabeled using the apparatusof the present invention through an automated synthetic scheme to yieldthe final form of the radiotracer.

II. Targeting Ligands

TA2S derivatives or DO2S derivatives may be used to target tumors (e.g.,cancerous, precancerous, benign), tumor angiogenesis, hypoxia, apoptosisdefects, disease receptors (e.g., cell receptors that are indicative ofcancer), disease functional pathways (e.g., a metabolic pathway that hasbeen altered by a disease state), and disease cell cycles. Additionally,TA2S derivatives or DO2S derivatives may be used for the assessment of apharmaceutical agent's effectiveness on these biochemical processes.

TA2S derivatives or DO2S derivatives may also be used as a diagnostictool and/or for predicting responses to certain kinds of treatment. Forexample, conjugates of TA2S derivatives or DO2S derivatives andtamoxifen (an estrogen receptor targeting ligand) may be used to imagecancerous tumors; in this example, the imaging may provide importantinformation about the disease such as to what degree the cancerous cellsexpress the estrogen receptor which can be used to predict how thedisease will respond to treatments that target cells expressing theestrogen receptor (e.g., when it is identified that cancerous tumorsselectively express high levels of estrogen receptor, this informationindicates that the cancerous cells will likely respond to therapeuticdoses of anti-cancer agents that target cells expressing the estrogenreceptor). This approach is referred to as “image guided therapy”.

An advantage of conjugating a TA2S derivative or DO2S derivative with atissue targeting ligands is that the specific binding properties of thetissue targeting ligand can concentrate the radioactive signal over thearea of interest. It is envisioned that the derivatives used for imagingand/or therapy may comprise a TA2S derivative or DO2S derivativeconjugated to a targeting ligand design for targeting cancerous tumors,pre-cancerous tumors, disease receptors, hypoxic tissues (hypoxia),apoptosis pathways, disease cell cycles, and/or disease functionalpathways. The TA2S derivatives or DO2S derivatives may also be used forassessing a pharmaceutical agent's effectiveness on various metabolicand/or biochemical pathways or individual reactions. Examples of certaintargeting ligands which may be used the present invention can be foundin Table 1. In certain embodiments, an anti-cancer drug may be used as atargeting ligand. Anti-cancer drugs are well known in the art (e.g.,Connors, 1996). For example, a table from U.S. Pat. No. 6,692,724 listsseveral examples of anti-cancer drugs which may be used as targetingligands in various embodiments of the present invention. U.S. Pat. No.6,692,724 is incorporated by reference as though fully disclosed herein.

TABLE 1 Targets for DO2S Examples of Derivatives Targeting Ligands TumorAngiogenesis Celecoxib, C225, angiostatin Disease Receptor tamoxifen,α-β tyrosine, tyrosine, alpha methyltyrosine, luteinizing hormone,transferrin, somatostatin, androgen, estrogen, estrone, progesterone,tetraacetate mannose, Disease Cell Cycle adenosine, penciclovirPharmaceutical Agent carnitine, puromycin Assessment Apoptosis TargetingTRAIL monoclonal antibody, caspase-3 substrate, Bel family member

Classes of Targeting Molecules

In the present invention, it is generally preferable to conjugate atargeting moiety (e.g., an anticancer drug) to the TA2S derivative orDO2S derivative; however, in certain embodiments a TA2S or DO2Sderivative that is not conjugated to a targeting moiety may be used forimaging and therapy. A targeting moiety may be conjugated to the TA2S orDO2S derivative via several methods. One method is to synthesize ahalide (e.g., iodinated) targeting moiety. For example, the hydroxygroup of a targeting moiety (e.g., a hydrophobic molecule) may beconverted to a tosyl-, mesyl-, triflate or halide (e.g., iodine) group,In certain embodiments of the present invention, the final product issoluble in water after hydrochloride or sodium salt formation.Alternatively, another method to conjugate DO2S compound to a targetingmoiety is to synthesize a sulfonate (e.g., tosyl- mesyl or triflate)targeting moiety. Di-, tri- or all substitutes on the DO2S derivativemay be prepared by reacting these iodinated or sulfonate targetingagents. For mono-substitutes on the carbonyl group, a selectiveprotection of nitrogen groups is needed. Targeting ligands that may beconjugated with a TA2S or DO2S derivative include amino acids (e.g.,tyrosine, serine), amino acid derivatives (e.g., alphamethyltyrosine),glucosamine, estrone, and tetraacetate mannose.

Other ligands may also be conjugated to the TA2S or DO2S derivative. Ingeneral, the ligands for use in conjunction with the present inventionwill possess either a halide or a hydroxy group that are able to reactwith and covalently bind to the TA2S or DO2S derivative on either one orboth acid arms and/or on one or both amino arms. Ligands contemplatedfor use in the present invention include, but are not limited to,angiogenesis/antiangiogenesis ligands, DNA topoisomerase inhibitors,glycolysis markers, antimetabolite ligands, apoptosis/hypoxia ligands,DNA intercalators, receptor markers, peptides, nucleotides,antimicrobials such as antibiotics or antifungals, organ specificligands and sugars, and agents that mimic glucose.

It is contemplated that virtually any targeting ligand that is known, ormay be subsequently discovered, that possesses a hydroxy group or ahalide, or alternatively may have a hydroxy group or halide introducedinto its structure (e.g., via the addition of a sidechain, or byattaching a halide to a phenol group in the targeting ligand), may beused with the present invention. In certain embodiments, a targetingligand may be directly conjugated to a TA2S or DO2S derivative, or atargeting ligand may be indirectly conjugated to a TA2S or DO2Sderivative via a linker. It is envisioned that targeting ligands thathave previously been conjugated to another (non-TA2S or DO2s compound)chelator, such as diaminodithiol chelators, may be conjugated to TA2S orDO2S derivative of the present invention and used for therapeuticpurposes; in certain instances, it may be required to modify thetargeting ligand (e.g., adding a side chain that contains a hydroxyl ora halide) in order to covalently bind the targeting ligand to the TA2Sor DO2S derivative.

Classes of targeting molecules include, but are not limited to, diseasecell cycle targeting compounds, angiogenesis targeting ligands, tumorapoptosis targeting ligands, disease receptor targeting ligands,drug-based ligands, antimicrobials, agents that mimic glucose, tumorhypoxia targeting ligands, extracellular matrix targeted ligands, andthe

1. Cellular Proliferation

Disease cell cycle targeting refers to the targeting of agents that areupregulated in proliferating cells. Compounds used for this purpose arealso known as proliferation targeting ligands and can be used to measurevarious parameters in cells, such as tumor cell DNA content. Certaindisease cell cycle targeting ligands are nucleoside analogues. Forexample, pyrimidine nucleosides (e.g.,2′-fluoro-2′-deoxy-5-iodo-1-β-D-arabinofuranosyluracil (FIAU),2′-fluoro-2′-deoxy-5-iodo-1-β-D-ribofuranosyl-uracil (FIRU),2′-fluoro-2′-5-methyl-1-β-D-arabinofurano-syluracil (FMAU),2′-fluoro-2′-deoxy-5-iodovinyl-1-β-D-ribofuranosyluracil (IVFRU) andacycloguanosine: 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine(PCV) (Tjuvajev et al, 2002; Gambhir et al., 1998; Gambhir et al., 199)and other 18F-labeled acycloguanosine analogs, such as8-fluoro-9-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine (FGCV)(Gambhir et al., 1999; Namavari et al., 2000),8-fluoro-9-[4-hydroxy-3-(hydroxymethyl)butyl]guanine (FPCV) (Gambhir etal., 2000; Iyer et al., 2001), 9-[3-fluoro-1-hydroxy-2-propoxymethyl]guanine (FHPG) (Alauddin et al., 1996; Alauddin et al., 1999),and 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine (FHBG) (Alauddin andConti, 1998; Yaghoubi et al., 2001) have been developed as re portersubstrates for imaging wild-type and mutant (Gambhir et al., 2000)HSV1-tk expression. Any combination of the foregoing are useful in thepractice of the invention. One of ordinary skill in the art would befamiliar with these and other agents that are used for disease cellcycle targeting.

2. Angiogenesis Targeting

Throughout this application, “tumor angiogenesis targeting” refers tothe use of an agent to bind to tumor neovascularization and tumor cells.Agents that are used for this purpose are known to those of ordinaryskill in the art for use in performing various tumor measurements,including measurement of the size of a tumor vascular bed, andmeasurement of tumor volume. Some of these agents bind to the vascularwall. One of ordinary skill in the art would be familiar with the agentsthat are available for use for this purpose. A tumor angiogenesistargeting ligand is a ligand that is used for the purpose of tumorangiogenesis targeting as defined above. Examples of angiogenesistargeting ligands include COX-2 inhibitors, anti-EGF receptor ligands,herceptin, angiostatin, C225, VEGF, RGD peptides, α_(v)β₃, NGR peptides,and thalidomide. COX-2 inhibitors include, for example, celecoxib,rofecoxib, etoricoxib, and analogs of these agents. Any combination ofthe foregoing are useful in the practice of the invention.

3. Tumor Apoptosis Targeting

“Tumor apoptosis targeting” refers to the use of an agent to bind to acell that is undergoing apoptosis or is at risk of undergoing apoptosis.These agents are generally used to provide an indicator of the extent orrisk of apoptosis, or programmed cell death, in a population of cells,such as a tumor. Significant research is directed towards the creationand evaluation of new compounds that affect apoptosis, such as restoringapoptosis sensitivity to cancer cells (Reed, 2003). It is envisionedthat the present invention may be used to expedite the evaluation and/orefficacy of known and/or subsequently discovered tumor apoptosistargeting compounds. One of ordinary skill in the art would be familiarwith agents that are used for this purpose. Certain examples ofapoptosis targeting agents are shown in Table 1. A “tumor apoptosistargeting ligand” is a ligand that is capable of performing “tumorapoptosis targeting” as defined in this paragraph. Examples of tumorapoptosis ligands include a TRAIL (TNF-related apoptosis inducingligand) monoclonal antibody. TRAIL is a member of the tumor necrosisfactor ligand family that rapidly induces apoptosis in a variety oftransformed cell lines. Other examples of tumor apoptosis targetingligands include a substrate of caspase-3, such as peptide or polypeptidethat includes the 4 amino acid sequence aspartic acid-glutamicacid-valine-aspartic acid, and any members of the Bcl, PRELI-MSF-1 andApoptosis Inducing Factor (AIF) families.

4. Disease Receptor Targeting

In “disease receptor targeting,”certain agents are exploited for theirability to bind to certain cellular receptors that are overexpressed indisease states, such as cancer. Examples of such receptors which aretargeted include estrogen receptors, amino acid transporters, androgenreceptors, pituitary receptors, transferrin receptors, progesteronereceptors, ABC family drug transporters, chemokine receptors, cytokinereceptors, hormone receptors, stem cell markers and glucosetransporters. Examples of agents that can be applied in disease-receptortargeting are shown in Table 1. Disease receptor targeting ligands(e.g., pentetreotide, octreotide, transferrin, and pituitary peptide)bind to cell receptors, some of which are overexpressed on certaincells. The folate receptor is included herein as another example of adisease receptor.

Estrogen, estrone, and tamoxifen target the estrogen receptor. Estrogenreceptors are over expressed in certain kinds of cancer, and DO2Sderivatives that comprise an estrogen receptor targeting ligand may beused in certain embodiments to image tumors. The expression of estrogenreceptors is also altered in the diseases of osteoporosis andendometriosis. It is anticipated that a DO2S derivative comprising anestrogen receptor targeting ligand may be used to image other diseasessuch as osteoporosis and endometriosis.

Glucose transporters are overexpressed in various diseased cells such ascertain cancerous cells. Tetraacetate mannose, deoxyglucose, certainpolysaccharides (e.g., neomycin, kanamycin, tobramycin), andmonosaccharides (e.g., glucosamine) also bind the glucose transporterand may be used as disease receptor targeting ligands. Since theseligands are not immunogenic and are cleared quickly from the plasma,receptor imaging would seem to be more promising compared to antibodyimaging.

Similarly, amino acid transporters are also overexpressed in variousdiseased cells such as certain cancerous cells. Amino acids and/or aminoacid derivatives (e.g., serine, tyrosine, alpha methyltyrosine) may beused as disease receptor targeting ligands.

The ATP-binding cassette (ABC) family of transporters are overexpressedin tumors and have been shown to regulate multidrug resistance. Membersof this family include MRP-1, p-glycoprotein, LRP, BCRP, CFTR OABP andthe GNC20 family. Examples of ABC family substrates which could beconjugated to DO2S compounds include verapamil, quinidine, diltiazen,ritonavir, docetaxel, topoisomerase inhibitors, 2-methoxy isobutylisonitrile (MIBI) and cyclosporine A.

Additional receptor targeting ligands are available and may beconjugated to DO2S compounds. Stem cell and progenitor cell surfacemarkers are overexpressed in tumors. Ligands which bind to thesereceptors include members of the notch, WNT, tumor growth factor (TGF),cadherin, desmoglien, and hedgehog families, alphafetoprotein,shyaluronic acid, erythropoietin, stem cell factor (STF), as well asligands to CD34, CD-44, c-kit, Sca-1 and CD133. Other examples ofdisease receptor targeting ligands include leuteinizing hormone andtransferrin. Folic acid, folate tomudex, and methotrexate are examplesof disease receptor targeting ligands that bind folate receptors.

“Tumor targeting” refers to the ability of a compound to preferentiallyassociate with tumors (e.g., cancerous, pre-cancerous, and/or benign). A“tumor targeting ligand” refers to a compound which preferentially bindsto or associates with tumor tissues, as compared to non-tumor tissues.Ligands (e.g., small molecules or antibodies) which preferentiallytarget tumors are well known in the art, and it is anticipated thattumor targeting ligands that are currently known, or which may besubsequently discovered, may be used with the present invention.

5. Drug-Based Ligands

Certain drug-based ligands can be applied in measuring thepharmacological response of a subject to a drug. A wide range ofparameters can be measured in determining the response of a subject toadministration of a drug. One of ordinary skill in the art would befamiliar with the types of responses that can be measured. Theseresponses depend in part upon various factors, including the particulardrug that is being evaluated, the particular disease or condition forwhich the subject is being treated, and characteristics of the subject.Examples of drug-based ligands include carnitine and puromycin.

6. Microbial Agents

Any antimicrobial is contemplated for inclusion as a targeting ligand.Preferred antimicrobials include ampicillin, amoxicillin, penicillin,cephalosporin, clidamycin, gentamycin, kanamycin, neomycin, natamycin,nafcillin, rifampin, tetracyclin, vancomycin, bleomycin, and doxycyclinfor gram positive and negative bacteria and amphotericin B, amantadine,nystatin, ketoconazole, polymycin, acyclovir, and ganciclovir for fungi.

7. Agents That Mimic Glucose

Agents that mimic glucose (glucose-mimicking agents) are alsocontemplated for inclusion as targeting ligands. Preferred agents thatmimic glucose, or sugars, include neomycin, kanamycin, gentamycin,paromycin, amikacin, tobramycin, netilmicin, ribostamycin, sisomicin,micromicin, lividomycin, dibekacin, isepamicin, astromicin,aminoglycosides, glucose or glucosamine.

Disease cell glycolysis targeting refers to the targeting of agents thatare upregulated in glucose utilization in cells. Compounds used for thispurpose can be used to measure various parameters in cells, such astumor cell growth, inflammation degrees. Certain disease cell glycolysistargeting ligands are glucose, galactose, mannose and ribose analogues.

8. Hypoxia Targeting

In certain embodiments, a tumor targeting ligand may associate withtumor tissues by targeting the hypoxia associated with tumor cells.Examples of tumor targeting ligands that target hypoxic tissues (hypoxiatargeting agents) include nitroimidazole and metronidazole, and theseligands may also be used to target other hypoxic tissues that arehypoxic due to a reason other than cancer (e.g., stroke).

Tumor hypoxia targeting ligands are also useful in certain embodimentsof the present invention. Misonidazole, an example of a tumor hypoxiatargeting ligand, is a hypoxic cell sensitizer, and labeling MISO withdifferent radioisotopes (e.g., ⁶⁸Ga, ^(99m)Tc, ¹¹¹In) may be useful fordifferentiating a hypoxic but metabolically active tumor from a welloxygenated active tumor by PET or planar scintigraphy.[¹⁸F]Fluoromisonidazole (FMISO) has been used with PET to evaluate tumorhypoxia.

Disease cell hypoxia targeting refers to the targeting of agents thatare upregulated in hypoxia cells. Compounds used for this purpose can beused to measure various parameters in cells, such as tumor cell hypoxia,resistance or residual content.

9. Extracellular Matrix and Lipid Raft Targeted Ligands

Extracellular matrix (ECM) proteins have been implicated in multipledisease states including inflammation, atherosclerosis, andtumorogenesis. Examples of ECM targeted ligands included agrin,thrompospondin, and members of the collagen, matrilin and lamininfamilies. Fibronectin and endostatin are also examples of ECM targetedligands. Plasma membrane lipids are involved in compartmentalizingsignal transduction events initiated by cell adhesion to theextracellular matrix. Examples of lipid raft-associated targets includeligands which bind integrins, cholesterol, sphigolipids,glycosylphosphatidylinositol (GPI)-anchored proteins and Rho and Racfamily GTPases.

III. Formulation of TA2S and DO2S Derivatives

To quench the radiolabeling reaction, a transchelator can be added tothe radioactive solution to chelate any unbound radioisotope. Examplesof acceptable transchelators for radionuclides include polycarboxylicacids, e.g., tartrate, citrate, pthalate, iminodiacetate, DOTA, EDTA,DTPA and the like. Additionally, any of a variety of anionic and/orhydroxylic oxygen-containing species could service this function, e.g.,salicylates, acetylacetonates, hydroxyacids, catechols, glycols andother polyols, e.g., glucoheptonate, and the like. Other suitablereagents and protocols for the formulation of radiopharmaceuticals willbe apparent to those skilled in the art and may be readily adapted foruse with the apparatus of the present invention.

IV. Linkers

If amino or hydroxy groups are not available (e.g., acid functionalgroup), a desired ligand may still be conjugated to the TA2S or DO2Sderivative using the methods of the invention by adding a linker, suchas ethylenediamine, amino propanol, diethylenetriamine, aspartic acid,polyaspartic acid, glutamic acid, polyglutamic acid, lysine,poly(ethylene) glycols or any combination thereof. For example, U.S.Pat. No. 6,737,247 discloses several linkers which may be used with thepresent invention and is hereby incorporated by reference in itsentirety without disclaimer. U.S. Pat. No. 5,605,672 discloses several“preferred backbones” which may be used as linkers in the presentinvention and is hereby incorporated by reference in its entirety. Incertain embodiments, a TA2S or DO2S compound may be conjugated to alinker, and the linker is conjugated to the targeting ligand. In otherembodiments more than one linker may be used; for example, a TA2S orDO2S derivative may be conjugated to a linker, and the linker isconjugated to a second linker, wherein the second linker is conjugatedto the targeting ligand. In, certain embodiments, two, three, four, ormore linkers that are conjugated together may be used to conjugate aTA2S or DO2S derivative and targeting ligand. However, it is generallypreferable to only use a single linker to conjugate a TA2S or DO2Sderivative and a targeting ligand.

V. Conjugates

The term “tetraaza compound conjugate” is defined herein as an tetraazacompound that has been conjugated to at least one other molecule oratom. In certain embodiments the tetraaza compound conjugate comprises atetraaza compound that has an atom chelated to it. The tetraaza compoundconjugate may comprise a tetraaza compound that is conjugated to atargeting ligand (via a covalent bond) and/or a linker (via a covalentbond) and/or a metal chelate (via a coordination bond). The term “TA2Sconjugate” is defined herein as an TA2S derivative that has beenconjugated to at least one other molecule or atom. In certainembodiments the TA2S conjugate comprises a TA2S derivative that has anatom chelated to it. The TA2S conjugate may comprise a tetraaza compoundthat is conjugated to a targeting ligand and/or a linker and/or a metalchelate (via a coordination bond). The term “DO2S conjugate” is definedherein as a DO2S derivative that has been conjugated to at least oneother molecule or atom. In certain embodiments the DO2S conjugatecomprises a DO2S derivative that has an atom chelated to it. The DO2Sconjugate may comprise a tetraaza compound that is conjugated to atargeting ligand and/or a linker and/or a metal chelate (via acoordination bond).

In this way, the derivatives may have a metal atom chelated to them(i.e., the conjugate may be labeled with a radioisotope). The metal atommay be radioactive or non-radioactive.

VI. Radioisotope Labeling

To facilitate certain embodiments involving, for example, imaging or theuse of a TA2S or DO2A derivative as a therapeutic, a radioisotope may bechelated to the TA2S or DO2A derivative. For example, a DO2A derivativemay be labeled with ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga,⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(99m)Tc, ¹¹¹In, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁸⁶Re, ¹⁷⁷Lu,¹⁸⁸Re, ²¹¹At, ²¹²Bi, ²²⁵Ac.

Generally, it is believed that virtually any α-emitter, β-emitter,γ-emitter, or β/γ-emitter can be used in conjunction with the invention.Preferred α-emitters include ²¹¹At, ²¹²Bi and ²²³Ra. Preferredβ-emitters include ⁹⁰Y and ²²⁵Ac. Preferred β/γ-emitters include ⁶⁷Cu,⁸⁹Sr, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re and ¹⁸⁸Re. Preferred γ-emitters include⁶²Cu, ⁶⁴Cu, ⁶⁷Ga, ⁶⁸Ga, ^(94m)Tc, ^(99m)Tc and ¹¹¹In. It is alsoenvisioned that para-magnetic substances, such as Gd, Mn, Cu or Fe canbe chelated with DO2S derivatives for use in conjunction with thepresent invention.

In nuclear imaging, the radiolabel is typically a γ radiation emittingradionuclide and the radiotracer is typically visualized using agamma-radiation detecting camera (this process is often referred to asgamma scintigraphy). The imaged site is detectable because theradiotracer is chosen either to localize at a pathological site (termedpositive contrast) or, alternatively, the radiotracer is chosenspecifically not to localize at such pathological sites (termed negativecontrast).

A variety of radioisotopes are known to be useful for nuclear imagingand radionuclide therapy, including ⁶⁷Ga, ⁶⁸Ga, ^(94m)Tc, ^(99m)Tc,¹¹¹In, ¹²³I, ¹²⁵I, ¹⁶⁹Yb, ¹⁷⁷Lu, ¹⁸⁶Re and ¹⁸⁸Re. Due to better imagingcharacteristics and cost-effectiveness, attempts have been made toreplace or provide an alternative to ¹¹¹In-labeled compounds withcorresponding ⁶⁸Ga labeled compounds when possible. Due to favorablephysical characteristics as well as availability from a generator, ⁶⁸Gais preferred for the labeling of diagnostic radiopharmaceuticals.

Numerous types of generator systems are known to those skilled in theart and any generator system that produces a sufficient quantity of adaughter nuclide can be useful in medical imaging including, but notlimited to: ⁴⁴Ti/⁴⁴Sc, ⁵²Fe/^(52m)Mn, ⁶²Zn/⁶²Cu, ⁶⁸Ge/⁶⁸Ga, ⁷²Se/⁷²As,⁸²Sr/⁸²Rb, ⁹⁹Mo/^(99m)Tc, ¹¹⁸Te/¹¹⁸Sb, ¹²²Xe/¹²²I, ¹²⁸Ba/¹²⁸Cs,¹⁷⁸W/¹⁷⁸Ta, ¹⁸⁸W/¹⁸⁸Re, ^(195m)/Hg/^(195m)Au.

A number of factors must be considered for optimal radioimaging inhumans. In certain embodiments, the TA2S or DO2A derivative may belabeled with ⁶⁸Ga for PET imaging or ¹⁷⁷Lu (a β and γ-emitter) forsystemic radionuclide therapy. When chelated with non-radioactive metals(e.g. copper, cobalt, platinum, iron, arsenic, rhenium, germanium), thecold (non-radioactive) TA2S or DO2A derivative may be used as a metallicchemotherapeutic agent. One aspect of the uniqueness of this technologyis to use existing PET sulfonate precursors or SPECT iodinated agents toreact with a DO2A compound and produce a chelator-based analogue of suchagents. The end product may then be used to chelate metals, which haveless complex chemistries and are more accessible and affordable thannon-metallic radionuclides.

Gallium-68 is a positron-emitting radioisotope produced from a ⁶⁸Ge/⁶⁸Gagenerator (t_(1/2)=271 days). Commercially-available ⁶⁸Ge/⁶⁸Gagenerators use diluted forms of hydrochloric acid for elution. Theeluate is collected in large volumes and is not in a suitable form forradiolabeling of pH sensitive materials or amenable to typical in vitroand in vivo studies. Therefore, removal of HCl is desired and can beachieved through evaporation or ion-exchange methods yielding aconcentrated solution of ⁶⁸Ga. The resulting ⁶⁸Ga³⁺ cation can formstable complexes with many ligands containing oxygen, nitrogen andsulfur as donor atoms, making it suitable for complexation with a widerange of chelators and macromolecules. For certain embodiments of thepresent invention involving chelating ⁶⁸Ga to TA2S or DO2S derivative orto a TA2S or DO2S conjugate, it is typically preferable that ⁶⁸Ga be inaqueous buffer solutions, most preferably in sodium acetate buffer.These solutions provide an ideal environment for forming the chelatewith TA2S or DO2S derivative or a TA2S or DO2S conjugate. It is known tothose having skill in the art that various buffers can also be usedduring ⁶⁸Ga chelation.

Therapeutic radionuclides emit radiation which interacts with tissuesand cellular components typically resulting in cellular damage.Virtually any α-emitter, β-emitter, or auger electron-emitter can exerta therapeutic effect on its target. Pure β-emitters have longerpathlengths in tissue and are preferred for larger tumors, however theylack imaging capabilities and utilize a diagnostic surrogate to providebiodistribution and dosimetry information. Certain radionuclides possessboth β and γ-emissions allowing for a diagnostic scan of the agent usinglow radioactive doses, followed by increasing radioactive doses to treatthe site of interest. ¹⁷⁷Lu is an example of a β/γ-emitting radionuclidewhich can be used with this invention to prepare a targeted agent withdiagnostic and therapeutic characteristics. Other examples ofβ/γ-emitters include ⁸⁹Sr, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁸⁶Re and ¹⁸⁸Re. Due tofavorable decay characteristics such as half-life (6.73 days), betaemission (490 keV) and gamma emission (113 keV [6.4%], 208keV [11%]) forimaging, ¹⁷⁷Lu is preferred for the labeling of therapeuticradionuclides.

In addition to imaging tumors with TA2S or DO2S derivatives labeled withradionuclides, it is envisioned that these compounds may also be usedfor imaging of tissue related to other diseases, as well as diagnosticsrelated to cancer and other diseases. For example, it is contemplatedthat the TA2S or DO2S derivatives labeled with radionuclides of theinvention may be useful to image not only tumors, but also othertissue-specific conditions, such as infection, hypoxic tissue (stroke),myocardial infarction, apoptotic cells, Alzheimer's disease andendometriosis. An advantage of imaging using a TA2S or DO2S derivativethat comprises a radiolabeled TA2S or DO2S derivative that is conjugatedto a tissue targeting ligand is that the specific binding properties ofthe tissue targeting ligand concentrates the radioactive signal over thearea of interest.

VII. Kit for Preparing Radiolabeled DO2S Conjugates

Complexes and means for preparing such complexes may be provided in akit form that typically includes a sealed vial containing apredetermined quantity of a TA2S or DO2S conjugate of the invention tobe labeled with a radionuclide. In some embodiments of the presentinvention, the kit includes a radionuclide. In certain furtherembodiments, the radionuclide is ⁶⁸Ga or ¹⁷⁷Lu. The kit may also containconventional pharmaceutical adjunct materials such as, for example,pharmaceutically acceptable salts to adjust the osmotic pressure,buffers, preservatives, antioxidants, and the like. Reducing agents mayalso be included in kits when the radioisotope is ^(99m)Tc or ¹⁸⁸Re.

In certain embodiments, an antioxidant and a transchelator are includedin the composition to prevent oxidation of the TA2S or DO2S conjugate.In certain embodiments, the antioxidant is vitamin C (ascorbic acid).However, it is contemplated that any other antioxidant known to those ofordinary skill in the art, such as gentistic acid, tocopherol,pyridoxine, thiamine, or rutin, may also be used. Examples oftranschelators for use in the present invention include, but are notlimited to, glucoheptonate, gluconate, glucarate, citrate, andtartarate. The components of the kit may be in liquid, frozen or dryform. In certain embodiments, kit components may be provided inlyophilized form.

VIII. Uses for DO2S Conjugates

The TA2S or DO2S conjugates of the invention may also be used forprognostic purposes. It is envisioned that TA2S or DO2S conjugates maybe administered to a patient having a tumor. It is envisioned that theuse of a radiolabeled TA2S or DO2S conjugates as a labeling strategy canbe effective using ligands designed for targeting disease receptors,hypoxia markers, apoptosis defects, disease cell cycles, diseasefunctional pathways, and assessment of pharmaceutical agentseffectiveness of these biochemical processes. Imaging may be performedto determine the effectiveness of the TA2S or DO2S conjugate against apatient's specific problem relating to disease receptors, hypoxiamarkers, apoptosis defects, disease cell cycles, disease functionalpathways, and assessment of pharmaceutical agent's effectiveness onthese biochemical processes. Using this methodology, physicians canquickly determine which TA2S or DO2S conjugate will be most effectivefor the patient and design the corresponding therapy or mode oftreatment. This methodology possesses significant advantages overmethods involving first choosing a drug and administering a cycle ofchemotherapy, which may involve months of the patient's time at asubstantial physical and financial cost before the effectiveness of thecancer chemotherapeutic agent can be determined.

The present invention may also be used to monitor the progress of formerpatients who have successfully undergone chemotherapy or radiationtreatment to determine if cancer has remained in remission or ismetastasizing. People with a history of cancer in their family or whohave been diagnosed with a gene(s) associated with cancer may undergomonitoring by health professionals using the methodology of the currentinvention. The methods and pharmaceutical agents of the currentinvention may also be used by a health professional to monitor if cancerhas started to develop in a person with cancer risk factors, such asenvironmental exposure to carcinogens. Such methods to monitor theprogress and/or recurrence of cancer and other diseases, known to thoseof skill in the art, are all applicable to the present invention andthat the present invention may be used in such methods should beunderstood.

The present invention may also be used for the delivery of radionuclidetherapy. A therapeutic radionuclide may be chelated by a TA2S or DO2Sconjugate and used for targeted treatment of disease. For example, ¹⁷⁷Luhas a beta emission of 498 keV which is suitable for therapy, and italso possesses a gamma emission which can allow for accurate dosimetryand imaging of ¹⁷⁷Lu-conjugates. The ability to directly image andassess the biodistribution and dosimetry of therapeutic radionuclides invivo will assist in determining target specificity as well as validatingthe localization of dose over time. Chelation of ¹⁷⁷Lu to a TA2S or DO2Sconjugate would allow targeting of the radionuclide complex to tumorcells and spare non-target organs from unnecessary radiation dose. Othervariations, known to those having skill in the art upon a reading of this disclosure are included in the present invention.

The present invention includes embodiments that are useful for thetargeted delivery of metallic therapy. Toxic metals can be chelated toTA2S or DO2S conjugates and used for the treatment of cancer. Metals ofinterest include but are not limited to gallium, iron, arsenic andplatinum. For example, DO2S-derivative 1 conjugated to folic acid couldalso chelate platinum for folate receptor-targeted therapy in folatereceptor-positive cancers. It is envisioned that such an approach wouldincrease specificity of drug delivery with reduced systemic toxicitywhich is typically associated with non-targeted delivery of such metals.A radiotracer using the radioactive form of the respective metal couldbe developed and serve as a guide for biodistribution, selection ofresponse in different tumor types and pharmacokinetic characterization.This and related embodiments of the present invention will be known tothose having skill in the art upon a reading of the presentspecification.

IX. Drug Assessment

Certain drug-based ligands of the present invention can be applied inmeasuring the pharmacological response of a subject to a drug. A widerange of parameters can be measured in determining the response of asubject to administration of a drug. One of ordinary skill in the artwould be familiar with the types of responses that can be measured.These responses depend in part upon various factors, including theparticular drug that is being evaluated, the particular disease orcondition for which the subject is being treated, and characteristics ofthe subject. Radiolabeled agents can be applied in measuring drugassessment.

X. Pharmaceutical Preparations

Pharmaceutical compositions of the present invention comprise aneffective amount of a DO2S derivative of the present invention dissolvedor dispersed in a pharmaceutically acceptable carrier. The phrases“pharmaceutical” or “pharmacologically acceptable” refer to molecularentities and compositions that do not produce an adverse, allergic orother untoward reaction when administered to an animal, such as, forexample, a human, as appropriate. The preparation of a pharmaceuticalcomposition that contains at least one TA2S or DO2S derivative, such asa radiolabeled TA2S or DO2S derivative, or additional active ingredientwill be known to those of skill in the art in light of the presentdisclosure, as exemplified by Remington's Pharmaceutical Sciences, 18thEd. Mack Printing Company, 1990, incorporated herein by reference.Moreover, for animal (e.g., human) administration, it will be understoodthat preparations should meet sterility, pyrogenicity, general safetyand purity standards as required by FDA Office of Biological Standards.

As used herein, “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, coatings, surfactants, antioxidants,preservatives (e.g., antibacterial agents, antifungal agents), isotonicagents, absorption delaying agents, salts, preservatives, drugs, drugstabilizers, gels, binders, excipients, disintegration agents,lubricants, sweetening agents, flavoring agents, dyes, such likematerials and combinations thereof, as would be known to one of ordinaryskill in the art (see, for example, Remington's Pharmaceutical Sciences,18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated hereinby reference). Except insofar as any conventional carrier isincompatible with the active ingredient, its use in the therapeutic orpharmaceutical compositions is contemplated.

The DO2S derivatives of the present invention may comprise differenttypes of carriers depending on whether it is to be administered insolid, liquid or aerosol form, and whether it needs to be sterile forsuch routes of administration such as injection. The present inventioncan be administered intravenously, intradermally, intraarterially,intraperitoneally, intralesionally, intracranially, intraarticularly.intraprostaticaly, intrapleurally, intratracheally, intranasally,intravitreally, intravaginally, intrarectally, topically,intratumorally, intramuscularly, intraperitoneally, subcutaneously,subconjunctival, intravesicularlly, mucosally, intrapericardially,intraumbilically, intraocularally, orally, topically, locally,injection, infusion, continuous infusion, localized perfusion bathingtarget cells directly, via a catheter, via a lavage, in lipidcompositions (e.g., liposomes), or by other method or any combination ofthe forgoing as would be known to one of ordinary skill in the art (see,for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack PrintingCompany, 1990, incorporated herein by reference).

The actual dosage amount of a composition of the present inventionadministered to a patient can be determined by physical andphysiological factors such as body weight, severity of condition, thetype of disease being treated, previous or concurrent therapeuticinterventions, idiopathy of the patient and on the route ofadministration. The practitioner responsible for administration will, inany event, determine the concentration of active ingredient(s) in acomposition and appropriate dose(s) for the individual subject.

In certain embodiments, pharmaceutical compositions may comprise, forexample, at least about 0.1% of a TA2S or DO2S derivative. In otherembodiments, the active compound may comprise between about 2% to about75% of the weight of the unit, or between about 25% to about 60%, forexample, and any range derivable therein. In other non-limitingexamples, a dose may also comprise from about 0.1 mg/kg/body weight, 0.5mg/kg/body weight, 1 mg/kg/body weight, about 5 mg/kg/body weight, about10 mg/kg/body weight, about 20 mg/kg/body weight, about 30 mg/kg/bodyweight, about 40 mg/kg/body weight, about 50 mg/kg/body weight, about 75mg/kg/body weight, about 100 mg/kg/body weight, about 200 mg/kg/bodyweight, about 350 mg/kg/body weight, about 500 mg/kg/body weight, about750 mg/kg/body weight, to about 1000 mg/kg/body weight or more peradministration, and any range derivable therein. In non-limitingexamples of a derivable range from the numbers listed herein, a range ofabout 10 mg/kg/body weight to about 100 mg/kg/body weight, etc., can beadministered, based on the numbers described above.

In any case, the composition may comprise various antioxidants to retardoxidation of one or more component. Additionally, the prevention of theaction of microorganisms can be brought about by preservatives such asvarious antibacterial and antifungal agents, including, but not limitedto parabens (e.g., methylparabens, propylparabens), chlorobutanol,phenol, sorbic acid, thimerosal or combinations thereof.

The TA2S or DO2S derivative may be formulated into a composition in afree base, neutral or salt form. Pharmaceutically acceptable saltsinclude the salts formed with the free carboxyl groups derived frominorganic bases such as for example, sodium, potassium, ammonium,calcium or ferric hydroxides; or such organic bases as isopropylamine,trimethylamine, histidine or procaine.

In embodiments where the composition is in a liquid form, a carrier canbe a solvent or dispersion medium comprising, but not limited to, water,ethanol, polyol (e.g. glycerol, propylene glycol, liquid polyethyleneglycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes)and combinations thereof. The proper fluidity can be maintained, forexample, by the use of a coating, such as leeitbin; by the maintenanceof the required particle size by dispersion in carriers such as, forexample, liquid polyol or lipids; by the use of surfactants such as, forexample, hydroxypropylcellulose; or combinations thereof such methods.In many cases, it will be preferable to include isotonic agents, suchas, for example, sugars, sodium chloride or combinations thereof.

Sterile injectable solutions are prepared by incorporating the TA2S orDO2S derivative in the required amount of the appropriate solvent withvarious amounts of the other ingredients enumerated above, as required,followed by filtered sterilization. Generally, dispersions are preparedby incorporating the various sterilized active ingredients into asterile vehicle which contains the basic dispersion medium and/or theother ingredients. In the case of sterile powders for the preparation ofsterile injectable solutions, suspensions or emulsion, the preferredmethods of preparation are vacuum-drying or freeze-drying techniqueswhich yield a powder of the active ingredient plus any additionaldesired ingredient from a previously sterile-filtered liquid mediumthereof. The liquid medium should be suitably buffered if necessary andthe liquid diluent first rendered isotonic prior to injection withsufficient saline or glucose. The preparation of highly concentratedcompositions for direct injection is also contemplated, where the use ofDMSO as solvent is envisioned to result in extremely rapid penetration,delivering high concentrations of the active agents to a small area.

The composition must be stable under the conditions of manufacture andstorage, and preserved against the contaminating action ofmicroorganisms, such as bacteria and fungi. It will be appreciated thatendotoxin contamination should be kept minimally at a safe level, forexample, less than 0.5 ng/mg protein.

In particular embodiments, prolonged absorption of an injectablecomposition can be brought about by the use in the compositions ofagents delaying absorption, such as, for example, aluminum monostearate,gelatin or combinations thereof.

XI. Combinational Therapy

It is an aspect of this invention that TA2S or DO2S derivatives, such asa radiolabeled TA2S or DO2S derivative, of the present invention can beused in combination with another agent or therapy method, preferablyanother cancer treatment. The TA2S or DO2S derivative may precede orfollow the other agent treatment by intervals ranging from minutes toweeks. In embodiments where the other agent and expression construct areapplied separately to the cell, one would generally ensure that asignificant period of time did not expire between the time of eachdelivery, such that the agent and expression construct would still beable to exert an advantageously combined effect on the cell. Forexample, in such instances, it is contemplated that one may contact thecell, tissue or organism with two, three, four or more modalitiessubstantially simultaneously (i.e., within less than about a minute)with the TA2S or DO2S derivative. In other aspects, one or more agentsmay be administered within about 1 minute, about 5 minutes, about 10minutes, about 20 minutes about 30 minutes, about 45 minutes, about 60minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours,about 6 hours, about 7 hours about 8 hours, about 9 hours, about 10hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours,about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours,about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours,about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours,about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46hours, about 47 hours, to about 48 hours or more prior to and/or afteradministering the DO2S derivative. In certain other embodiments, anagent may be administered within of from about 1 day, about 2 days,about 3 days, about 4 days, about 5 days, about 6 days, about 7 days,about 8 days, about 9 days, about 10 days, about 11 days, about 12 days,about 13 days, about 14 days, about 15 days, about 16 days, about 17days, about 18 days, about 19 days, about 20, to about 21 days prior toand/or after administering the TA2S or DO2S derivative. In somesituations, it may be desirable to extend the time period for treatmentsignificantly, however, where several weeks (e.g., about 1, about 2,about 3, about 4, about 5, about 6, about 7 or about 8 weeks or more)lapse between the respective administrations.

Various combinations may be employed, the DO2S derivative is “A” and thesecondary agent, which can be any other therapeutic agent, is “B”:

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A  A/A/B/A

Administration of the therapeudic expression constructs of the presentinvention to a patient will follow general protocols for theadministration of chemotherapeutics, taking into account the toxicity,if any, of the vector. It is expected that the treatment cycles would berepeated as necessary. It also is contemplated that various standardtherapies, as well as surgical intervention, may be applied incombination with the TA2S or DO2S derivative. These therapies includebut are not limited to chemotherapy, radiotherapy, immunotherapy, genetherapy and surgery.

a. Chemotherapy

Cancer therapies also include a variety of combination therapies withboth chemical and radiation based treatments. Combination chemotherapyinclude, for example, cisplatin (CDDP), carboplatin, procarbazine,mechlorethamine, cyclophosphamide, camptothecin, ifosfamine, melphalam,chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin,doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16),tamoxifen, raloxifene, estrogen receptor binding agents, taxol,gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, COX-2inhibitors, cholesterol synthesis inhibitors, cisplatinum,5-fluorouracil, vincristin, vinblastin, methylxanthine derivatives,wortmanin, rapamycin, forskolin, staurosporine, streptozocin,fludurabine, methotrexate, genistcin, curcumin, resveratrol, silymarin,caffeic acid phenethyl ester, flavopiridol, emodin, green teapolyphenols, piperine, oleandrin, ursolic acid, butamic acid,actinomycin D, thalidomide or any analog or derivative variant of theforegoing.

b. Radiotherapy

Other factors that cause DNA damage and have been used extensivelyinclude what are commonly known as γ-rays, X-rays, and/or the directeddelivery of radioisotopes to tumor cells. Other forms of DNA damagingfactors are also contemplated such as microwaves and UV-irradiation. Itis most likely that all of these factors affect a broad range of damageon DNA, on the precursors of DNA, on the replication and repair of DNA,and on the assembly and maintenance of chromosomes. Dosage ranges forX-rays range from daily doses of 50 to 200 roentgens for prolongedperiods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens.Dosage ranges for radioisotopes vary widely and depend on the half-lifeof the isotope, the strength and type of radiation emitted, and t heuptake by the neoplastic cells. The terms “contacted” and “exposed,”when applied to a cell, are used herein to describe the process by whicha therapeutic construct and a chemotherapeutic or radiotherapeutic agentare delivered to a target cell or are placed in direct juxtapositionwith the target cell. To achieve cell killing or stasis, both agents aredelivered to a cell in a combined amount effective to kill the cell orprevent it from dividing.

c. Radiochemotherapy

Radiochemotherapy is the combined delivery of radiation and chemotherapyto a target. This can be achieved in a single agent through conjugationof a chemotherapeutic agent to a chelating moiety which is thensubsequently radiolabeled with a therapeutic radionuclide. Combinationsof radiochemotherapy include, for example, cisplatin (CDDP) withα-emitters, cyclophosphamide with β-emitters, doxorubicin withβ/γ-emitters and taxol with Auger-emitters, or any analog or derivativevariant of the foregoing.

d. Immunotherapy

Immunotherapeutics, generally, rely on the use of immune effector cellsand molecules to target and destroy cancer cells. The immune effectormay be, for example, an antibody specific for some marker on the surfaceof a tumor cell. The antibody alone may serve as an effector of therapyor it may recruit other cells to actually affect cell killing. Theantibody may also be conjugated to a drug or toxin (chemotherapeutic,radionucleotide, ricin A chain, cholera toxin, pertussis toxin, etc.)and serve merely as a targeting agent. Alternatively, the effector maybe a lymphocyte carrying a surface molecule that interacts, eitherdirectly or indirectly, with a tumor cell target. Various effector cellsinclude cytotoxic T cells and NK cells.

Immunotherapy could thus be used as part of a combined therapy, possiblyin conjunction with gene therapy. The general approach for combinedtherapy is discussed below. Generally, the tumor cell must bear somemarker that is amenable to targeting, i.e., is not present on themajority of other cells. Many tumor markers exist and any of these maybe suitable for targeting in the context of the present invention.Common tumor markers include carcinoembroynic antigen, prostate specificantigen, urinary tumor associated antigen, fetal antigen, tyrosinase(p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP,estrogen receptor, laminin receptor, erb B and p155.

e. Gene Therapy

In yet another embodiment, the secondary treatment is a secondary genetherapy in which a therapeutic polynucleotide is administered before,after, or at the same time a first therapeutic agent. Delivery of thetherapeutic agent in conjunction with a vector encoding a gene productwill have a combined anti-hyperproliferative effect on target tissues.

f. Surgery

Approximately 60% of persons with cancer will undergo surgery of sometype, which includes preventative, diagnostic or staging, curative andpalliative surgery. Curative surgery is a cancer treatment that may beused in conjunction with other therapies, such as the treatment of thepresent invention, chemotherapy, radiotherapy, hormonal therapy, genetherapy, immunotherapy and/or alternative therapies. Curative surgeryincludes resection in which all or part of cancerous tissue isphysically or partially removed, excised, and/or destroyed. Tumorresection refers to physical removal of at least part of a tumor. Inaddition to tumor resection, treatment by surgery includes lasersurgery, cryosurgery, electrosurgery, and miscopically controlledsurgery (Mohs' surgery). It is further contemplated that the presentinvention may be used in conjunction with removal of superficialcancers, precancers, or incidental amounts of normal tissue.

XII. Synthetic Pathways EXAMPLE 1 Synthesis of DO2A-Glucosamine

The N4 compound starting materials for the tetraaza compounds arecommercially available. Examples of how one would make the novelmodifications of these macrocyclic compounds for the present inventionherein are provided below.

This example illustrates the synthesis of DO2A-(Glucosamine)2.DO2A-tert-butyl ester (1,4,7,10-Tetraazacyclododecane-1,7-bis(t-butylacetate) (0.215 g, 0.538 mmoles) was dissolved in 2 ml of trifluroaceticacid, 0.1 mL of water, and 0.4 mL of methylene chloride. After stirringfor 2 h at room temperature, the solvent was evaporated under vacuum.The product was dissolved in 3 mL of methanol and 2 mL of water andextracted twice with 4 mL of methylene chloride. The aqueous layer wasconcentrated under vacuum to yield DO2A-(COOH)₂ as a light yellow oil.Product was dissolved in 1 mL of methanol and left at temperature 4° C.for 2 days yielding colorless crystals.

DO2A-(COOH)₂ (0.1748 g, 0.523 mmoles) was dissolved in 1.46 mL of DMSOand 0.122 mL of Et₃N, and 0.464 g of BOP(1H-benzotriazol-1-yloxy-tris(dimethylamino)phosphoniumhexafluorophosphate) was added. Reaction mixture was stirred for 1 h atroom temperature. Glucosamine hydrochloride (0.23 g, 1.046 mmoles)dissolved in 0.2 mL of Et₃N and 1.57 mL of DMSO/Et₂O (ratio 34:66 v/v)was added to pre-activated solution of DO2A(COOH)₂. Reaction mixture wasstirred at room temperature for 3 days. After solvent evaporation undervacuum, residue was dissolved in 4 mL of methanol and 1 mL of water andextracted twice with methylene chloride. The aqueous fraction wasconcentrated under vacuum, redissolved in 0.3 mL of methanol and 1 mL ofEt₂O, then stored at room temperature for 2-3 days yielding light yellowcrystals of product. Product was purified and analyzed by reverse phaseRP-HPLC (phenomenex, C18 column, UV detection at 251 and 280 mm) usingbinary gradient: 0%-25% buffer B (buffer A: H₂0+0.01% TFA, buffer B:CH₃CN+0.01% TFA), flow rate:0.3 mL/min.

EXAMPLE 2 Synthesis and Radiolabeling of⁶⁸Ga-(Glucosamine)₂-DO2A-(COOH)₂ and ⁶⁸Ga-(Glucosamine)₃-DO2A-COOHConjugates

This example illustrates the synthesis and radiolabeling of⁶⁸Ga-(Glucosamine)2-DO2A-(COOH)2 and ⁶⁸Ga-(Glucosamine)₃-D02A-COOHconjugates. To a solution of1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (0.145 g, 0.283mmoles) dissolved in 0.187 mL of DIPEA (N,N-disopropylethylamine) and9.76 mL of NMP (N-methyl-pyrrolindone), 0.430 g (1.132 mmoles) of HATUwas added. The reaction mixture was stirred for 20 min at roomtemperature. Glucosamine hydrochloride (1.132 mmoles, 0.244 mg) wasdissolved in 6 mL of NMP and 0.187 mL of DIPEA and added to apre-activated solution of DO2A-(COOH)₄. Reaction mixture was stirred atroom temperature for 24 h. After solvent evaporation, residue wasdissolved in 3 mL water and extracted with methylene chloride. Theaqueous layer was evaporated in vacuum yielding yellow oil. Product wasprecipitated with diethyl ether and analyzed by reverse phase RP-HPLC(Phenomenex, C18, UV detection at 251 and 280 nm using a binary gradient0%-45% buffer B (buffer A: H₂0, buffer B: CH₃CN+0.1% TFA) in 20 min,flow rate 2 mL/min. The product was a mixture of the of disubstitutedand trisubstituted D02A-glucosamine conjugates and was purified byRP-HPLC.

20 nmoles of (Glucosamine)₂-D02A-(COOH)2 was dissolved in sodium acetatebuffer (pH 4). ⁶⁸Ga was eluted from a ⁶⁸Ge/⁶⁸Ga generator and bufferedto pH 4 using solid sodium acetate. 50 μCi of ⁶⁸Ga was added to theconjugate and heated at 95° C. for 10 min. The labeling reaction wasmonitored using instant-thin-layer-chromatography with a mobile phase of0.1 M ammonium acetate:methanol (1:1 v/v) and quantified using aradio-TLC scanner (Bioscan). Radiochemical purity was >95%.

FIG. 1 provides synthetic scheme of D02A-bis(tert-Bu) ester (FIG. 1A)and synthetic pathways for the ligand attachment to a D02S derivativesand D02S derivative-I (FIG. 1B). It should be understood that schematicstructures of TA2S derivatives and even tetraaza compounds areanalogous. FIG. 1C. shows schemes that illustrate the attachment of oneor more than one ligand to the D02S ring. FIG. 1D. shows a tableproviding illustrative (non-limiting) examples of various ligands andthe coupling agents useful in the synthesis.

FIG. 2 illustrates the preparation of mono- and di-aminosugar-containingD02S derivatives labeled with radiometals. Deprotection of carboxylgroups of

D02A-bis(tert-Bu) ester or its derivatives proceed in the presence of IFA (trifluroacetic acid). The conjugation reaction of the D02A-acid tothe amino sugar (e.g. glucosamine hydrochloride, galactosaminehydrochloride) is performed by activation of carboxyl group of D02A byHB TU (0-benzotriazole-N,N,N′,N′-tetramethyluronium-hexafluorophosphate)and HOBT (1-hydroxybenzo-triazole) in the presence of DIEA(N,N-diisopropylethylamine) in DMF. The selectivity of this reaction iscontrolled by the temperature and stoichiometry of reagents. Method isused to prepare of D02S-dendrimers and their derivatives modified withpolyamino sugar ligands. See Y. Ye, S. Bloch, S. Achilefu, Journal ofthe American Chemical Society, 2004, 126 (25), 7740-7741.

The preparation of D02S derivatives containing somatostatin analogslabeled with radiometals is shown in FIG. 3A. Direct conjugation of theD02S derivative to the N-terminus of the selectively protectedsomatostatin analog octreotide is performed in the presence ofactivating reagents, NHS (N-hydroxysuccinimide) and DCCI(N,N-dicyclohexylcarbodiimide). This highly selective reaction does notrequire protection of carboxyl groups of the1,4,7,10-tetraazacyclododecane. The partially protected octapeptidesused in the coupling reactions can be synthesized in solid phase.Conjugates of the D02S derivative and octapeptide are treated with thetrifluroacetic acid (TFA) to remove N-Boc (t-butoxycarbonyl) protectinggroups from lysine to give D02S-octreotide derivatives. This methodallows for the preparation of D02S-somatostatin analogues containingnatural and non-natural amino acids with different side chains. See R.Albert, P. Smith-Jones, B. Stolz, C. Simeon, H. Knecht, C. Bruns, J.Pless, Bioorganic & Medicinal Chemistry Letters 1998, 8, 1207-1210.

FIG. 3B illustrates the scenano where it is desirable to modulatelipophilicity of the D02S-somatostatin analogues, different linkers canbe introduced between the D02S ring and octapeptide derivative eg.N-polyethylene glycol linkers (15-amino-4,7,10,13-tetraoxapentadecanoicacid PEG₄, 8-amino-3,6-dioxaoctanoic acid PEG₂); amino sugars(N-acetylglucosamine, N-acetylgalactosamine and their derivatives),natural and modified amino acids (Table 2). All DO2S-linker-somatostatinanalogues can be synthesized by Fmoc-solid phase synthesis onH-Thr(tBu)-ol-(2-chlorotrityl)-resin. The N-terminus of the linker orthe octapeptide is activated using the peptide coupling reagent, HATU(2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uraniumhexafluorophosphate) and then conjugated to the D02S. The conjugatesD02S-linker-octapeptide are cleaved from the resin using TFA. In orderto increase the somatostatin receptor affinity, different amino acidsare incorporated in the octapeptide octreotide sequence in positions 3and 8, and are used in the synthesis of D02S-linker-somatatostatinconjugates.

Preparation of D02S-EGF conjugates with radiometals is shown in FIG. 4.D02S-EGF-radiometals conjugates are synthesized by a three stepprocedure using the N-hydroxysuccinimide ester of D02S as a substrate.The deprotection reaction of the D02S carboxyl group and complexationreaction of the radioisotope to the tetraaza-compound give the D02S-EGFconjugates. See I. Velikyan et al., Journal of the Nuclear Medicine,2005, 46 (11), 1881-1888.

FIGS. 5A and B illustrates the preparation of the dual isotope labeledof D)02S derivatives; D02S derivatives conjugated to aliphatic andaromatic amines, amino acids, polyamines. FIG. 5A: The a-amino andcarboxylic groups of amino acids are protected with carbobenzyl (Cbz)and benzyl (Bn) groups, respectively 1. The primary amino group of theamino acid is selectively deprotected in the presence of TFA(trifluroacetic acid), 2. Reaction of the amino acid with thebromoacetyl bromide in the presence of the DIEA (1V,N-diisopropylethylamine) leads to the intermediate ester 3 which iscoupled to D02S. Protecting groups of the D02S derivatives are removedby catalytic hydrogenation to give D02S-modified amino acids 4. Thismethod is used to incorporate D02S in the exo- and endo-position of thepeptide. FIG. 5B: The reaction of the amino acid (or amino containingcompound) with D02S proceeds in the presence of the peptide couplingreagents, HBTU(0-Benzotriazole-N,N,N′,N′-tetramethyluronium-hexafluorophosphate)/HOBT(N-hydroxybenzotriazole)and DIEA. This method is used to prepare D02S conjugates carrying twodifferent labels (e.g. ^(99m)Tc and ¹⁸F).

FIG. 6 illustrates the oxathiaphospholane approach applied for thesynthesis of D02S-phosphate, phosphorothioate, phosphoroamides, andphosphorothioamides modified with lipophylic ligand. Theoxathiaphospholane approach is applied for the modification of D02Sderivatives usmg (thio)phosphate or phosphoro(thio)amides forconjugation to lipophilic ligands. The reaction of D02S derivative withthe 2-thiono-1,3,2-oxathiaphospholane ester proceed in the presence ofEt₃N or DBU with release of the episulfide as a side product. Thismethod allows for the preparation of D02S-derivatives linked to thesynthetic liposomes used as delivery vehicles for the chelating ligand.See G. W. Bailey, J. M. Corbett, R. V. W. Dimlich, J. R. Michael and N.J., Zaluzec; Proceedings of the fifty-fourth Annual Meeting, MicroscopySociety of America. San Francisco Press, San Francisco, Calif., 1996,pp. 898-899.

FIG. 7 provides a schematic pathway for the preparation of DO2Sconjugates with gold nanoparticles and carbon nanotubes.

FIG. 8 illustrates the modification of DO2S derivatives at the N₄ and/orN₁₀ position. The 2-bromo-N-modified acetamides alkylate the N₄ and/orN₁₀ aza-groups of the DO2A bis(t-butyl) ester. Deprotection of thecarboxyl groups of DO2S derivatives proceed in the presence oftrifluoroacetic acid. The carboxymethyl groups of N₄, N₁₀-disubstitutedtetraaza compounds can be functionalized with other ligands usingpreviously described methods.

Although the present invention and its advantages have been described indetail, it should be understood that various changes, substitutions andalterations can be made herein without departing from the invention asdefined by the appended claims. Moreover, the scope of the presentapplication is not intended to be limited to the particular embodimentsof the process, machine, manufacture, composition of matter, means,methods and steps described in the specification. As one will readilyappreciate from the disclosure, processes, machines, manufacture,compositions of matter, means, methods, or steps, presently existing orlater to be developed that perform substantially the same function orachieve substantially the same result as the corresponding embodimentsdescribed herein may be utilized. Accordingly, the appended claims areintended to include within their scope such processes, machines,manufacture, compositions of matter, means, methods, or steps.

What is claimed is:
 1. A composition, comprising: a TA2S derivativehaving the general formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof, and, wherein one of (R1 and R₃), or (R₂ andR₄) are the same or different and are hydrogen or a ligand, and theother of (R₁ and R₃), or (R₂ and R₄) are —(CH₂)_(n)—C(O)—R′, whereineach R′ group is the same or different from the other R′ group and iseither a hydroxyl group or a ligand; and wherein n=1-4.
 2. Thecomposition of claim 1, wherein A₁, A₂, A₃, and A₄ are each (—CH₂—CH₂)—groups and having the following structure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TA2S derivative is a DO2Sderivative.
 3. The composition of claim 2, having the followingstructure:

a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or, (b) (R₁ and R₃) are ligands and(R₁′ and R₂′) are the same or different and are a ligand or hydroxylgroup; and, and said DO2S derivative is a DO2S derivative-1.
 4. Thecomposition of claim 1, wherein said ligand is selected from the groupconsisting of a proliferation targeting ligand, an angiogenesistargeting ligand, a tumor apoptosis targeting ligand, a disease receptortargeting ligand, a drug-based ligand, a microbial agent, aglucose-mimicking agent, a hypoxia targeting agent, an extracellularmatrix targeting ligand, and any combination thereof.
 5. The compositionof claim 2, wherein said DO2S derivative further comprises at least onelinker, wherein said at least one linker forms a link to conjugate saidDO2S derivative to said ligand.
 6. The composition of claim 5, whereinsaid at least one linker is selected from the group consisting ofethylenediamine, amino propanol, diethylenetriamine, aspartic acid,polyaspartic acid, glutamic acid, polyglutamic acid, lysine,polyethylene glycols, and any combination thereof.
 7. The composition ofclaim 1, wherein said ligand is selected from the group consisting ofglucosamine, tetraacetate mannose, octreotide, Hedgehog ligands, EGFRtargeting molecules, nucleotides, nucleosides, cholesterol, estradiol,nanoparticles, carbon nanotubes, and any combination thereof.
 8. Thecomposition of claim 2, wherein the ligand is an anti-cancer compound.9. The composition of claim 2, wherein the ligand is a carbohydrate. 10.The composition of claim 2, wherein said DO2S derivative is chelated toa metal species.
 11. The composition of claim 10, wherein said metalspecies is copper, cobalt, platinum, iron, arsenic, rhenium, orgermanium.
 12. The composition of claim 10, wherein said metal speciesis a radionuclide.
 13. The composition of claim 12, wherein saidradionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga, ⁶⁸Ga,⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu,¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵Ac.
 14. The composition of claim 13,wherein said radionuclide is ⁶⁸Ga or ¹⁷⁷Lu.
 15. The composition of claim2, wherein said ligand comprises a drug.
 16. A method for the treatmentor diagnosis of a medical condition in a subject comprising:administering to the subject a composition, comprising: a TA2Sderivative having the general formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and, wherein one of (R₁ and R₃), or (R₂ andR₄) are the same or different and are hydrogen or a ligand, and theother of (R₁ and R₃), or (R₂ and R₄) are —(CH₂)_(n)—C(O)—R′, whereineach R′ group is the same or different from the other R′ group and iseither a hydroxyl group or a ligand; and wherein n=1-4.
 17. The methodof claim 16, wherein A₁, A₂, A₃, and A₄ are each —(CH₂—CH₂)— groups andhaving the Miming structure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TA2S derivative is a DO2Sderivative.
 18. The method of claim 17, wherein the composition has thefollowing structure:

a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or, (b) R₁ and R₃) are ligands and(R₁′ and R₂′) are the same or different and are a ligand or hydroxylgroup; and, and said DO2S derivative is a DO2S derivative-1.
 19. Themethod of claim 17, wherein the subject is a mammal
 20. The method ofclaim 19, wherein the mammal is a human.
 21. (canceled)
 22. The methodof claim 21, wherein said metal species is a radionuclide.
 23. Themethod of claim 22, wherein said radionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu,⁶²Cu, ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In,¹⁴⁹Pm, ¹⁵³Gd, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵Ac.24. The method of claim 23, wherein said radionuclide is ⁶⁸Ga or ¹⁷⁷Lu.25. The method of claim 21, wherein said metal species is selected fromthe group consisting of divalent ions of: an element of atomic number 21to 29, 42, 44, and 57 to 83; and, trivalent ions of an element of atomicnumber 21 to 29, 42, 44, and 57 to
 83. 26. The method of claim 17,further comprising administering radiation therapy or surgery.
 27. Themethod of claim 17, wherein said medical condition oondibon im cancerand said ligand is an anti-cancer compound,
 28. The method of claim 27,further comprising administration of a second anti-cancer compound. 29.The method of claim 17, wherein said ligand is selected from the groupconsisting of a proliferation targeting ligand, angiogenesis targetingligand, a tumor apoptosis targeting ligand, a disease receptor targetingligand, a drug-based ligand, a microbial agent, a glucose-mimickingagent, a hypoxia targeting agent, an extracellular matrix targetingligand, and. any combination thereof.
 30. The method of claim 17,wherein said DO2S derivative further comprises at least one linker,wherein said at least one linker forms a link to conjugate said DO2Sderivative to said ligand.
 31. The method of claim 30, wherein said atleast one linker is selected from the group consisting ofethylenediamine, amino propanol, diethylenetriamine, aspartic acid,polyaspartic acid, glutamic acid, polyglutamic acid, lysine,polyethylene glycols, and any combination thereof.
 32. The method ofclaim 17, wherein said ligand is selected from the group consisting ofglucosamine, tetraacetate mannose, octreotide, Hedgehog ligands, EGFRtargeting molecules, nucleotides, nucleosides, cholesterol, estradiol,nanoparticles, carbon nanotubes, and any combination thereof.
 33. Themethod of claim 17, wherein the ligand is an anti-cancer compound. 34.The method of claim 17, wherein the ligand is a carbohydrate.
 35. A kitfor the treatment or diagnosis of a medical condition in a subject, saidkit comprising: a composition comprising: a TA2S derivative conjugatedto a therapeutic or diagnostic ligand and optionally chelated to ametal, wherein said TA2S derivative comprises the general formula:

wherein A₁, A₂, A₃, and A₄ may be the same or different and are selectedfrom the group consisting of C₂-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,and any combination thereof; and, wherein one of (R₁ and R₃), or (R2 andR₄.) are the same or different and are hydrogen or a ligand, and theother of (R₁ and R₃), or (R₂ and R₄) are —(CH₂)_(n)—C(O)—R′, whereineach R′ group is the same or different from the other R′ group and iseither a hydroxyl group or a ligand; and wherein n=1-4.
 36. The kit ofclaim 35, wherein A₁, A₂, A₃ and A₄ are each —(CH₂—CH₂)— groups andhaving the following structure:

wherein (R₁ and R₃) are the same or different and are hydrogen or aligand and (R₁′ and R₂′) are the same or different and are a ligand or ahydroxyl group, and wherein n=1-4, and said TITA2S derivative is a DO2Sderivative.
 37. The kit of claim 36, wherein the DO2S derivative has thefollowing structure:

a) (R₁ and R₃) are hydrogen and (R₁′ and R₂′) are the same or differentand are a ligand or hydroxyl group; or, (b) (R₁ and R₃) are ligands and(R₁′ and R₂′) are the same or different and are a ligand or hydroxylgroup; and, and said DO2S derivative is a DO2S derivative-1.
 38. The kitof claim 36, wherein said metal is a radionuclide.
 39. The kit of claim38, wherein the radionuclide is ⁴⁵Ti, ⁵⁹Fe, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu,⁶⁷Cu, ⁶⁷Ga, ⁶⁸Ga, ⁸⁹Sr, ⁹⁰Y, ^(94m)Tc, ^(99m)Tc, ¹¹¹In, ¹⁴⁹Pm, ¹⁵³Gd,¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, ²¹²Bi or ²²⁵Ac.
 40. The kit ofclaim 39, wherein the radionuclide is ⁶⁸Ga or ¹⁷⁷Lu.
 41. The kit ofclaim 36, further comprising an antioxidant.
 42. The kit of claim 41,wherein the antioxidant is vitamin C, tocopherol, pyridoxine, thiamine,or rutin.
 43. The kit of claim 36, further comprising a transchelator.44. The kit of claim 43 wherein the transchelator is glucoheptonate,gluconate, glucarate, citrate, tartarate, DOTA,diethylenetriaminepentaacetic acid, or ethylenediaminetetraacetic acid.45. The kit of claim 36, further comprising a reducing agent.
 46. Thekit of claim 45, wherein said reducing agent is tin (II) chloride ortriphenylphosphine.
 47. The kit of claim 36, wherein said ligand is atumor targeting ligand.
 48. The kit of claim 36, wherein said ligand isselected from the group consisting of a proliferation targeting ligand,an angiogenesis targeting ligand, a tumor apoptosis targeting ligand, adisease receptor targeting ligand, a drug-based ligand, a microbialagent, a glucose-mimicking agent, a hypoxia targeting agent, anextracellular matrix targeting ligand, and any combination thereof. 49.The kit of claim 36, wherein said DO2S derivative further comprises atleast one linker, wherein said at least one linker forms a link toconjugate said DO2S derivative to said targeting ligand.
 50. The kit ofclaim 49, wherein said at least one linker is selected from the groupconsisting of ethylenediamine, amino propanol, diethylenetriamine,aspartic acid, polyaspartic acid, glutamic acid, polyglutamic acid,lysine, polyethylene glycols, and any combination thereof.
 51. The kitof claim 36, wherein said ligand is selected from the group consistingof glucosamine tetraacetate mannose, octreotide, Hedgehog ligands, EGFRtargeting molecules, nucleotides, nucleosides, cholesterol, estradiol,nanoparticles, carbon nanotubes, and any combination thereof.
 52. Thekit of claim 36, wherein the ligand is an anti-cancer compound.
 53. Thekit of claim 36, wherein the ligand is a carbohydrate.
 54. Thecomposition of claim 1, further comprising a metal comprising a metallicchemotherapeutic agent or a radiotherapeutic agent chelated to the T A 2S derivative.
 55. The composition of claim 2, wherein the DO2Sderivative comprises a phospholipid according to the following formula:

wherein Me is a metal.
 56. The composition of claim 2, wherein the DO2Sderivative comprises one of the following structures:

wherein L is a linker and Me is a metal.
 57. The method of claim 16,further comprising imaging said subject.
 58. The method of claim 16,wherein the TA2S derivative comprises a DO2S derivative, the methodfurther comprising synthesizing the TA2S derivative by attaching aligand to the DO2S derivative by replacing the hydrogen at the (R₁ andR₃) with the ligand.
 59. The method of claim 58, wherein thesynthesizing comprises:


60. The method of claim 16, wherein the TA2S derivative comprises a DO2Sderivative and wherein the (R2 and R4) are —(CH2)n—C(O)—R′, the methodfurther comprising synthesizing the TA2S derivative by attaching theligand to the DO2S derivative by replacing the R′ with the ligand. 61.The meth of claim 60, wherein the synthesizing comprises:


62. The method of claim 16, wherein the TA2S derivative comprises a DO2Sderivative, the method further comprising synthesizing the TA2Sderivative by attaching a peptide to the DO2S derivative.
 63. The methodof claim 62, wherein the synthesizing comprises:

wherein Cbz are carbobenzyl groups, Bn are benzyl groups, and Me is ametal.